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A B S T R A C T
Background
Chronic limb-threatening ischaemia (CLTI) is a manifestation of peripheral arterial disease (PAD) that includes chronic ischaemic rest
pain or ischaemic skin lesions, ulcers, or gangrene for longer than two weeks. The severity of the disease depends on the extent of arterial
stenosis and the availability of collateral circulation. Treatment for CLTI aims to relieve ischaemic pain, heal ischaemic ulcers, prevent
limb loss, improve quality of life, and prolong survival. CLTI due to occlusive disease in the infrapopliteal arterial circulation (below-
knee circulation) can be treated via an endovascular technique by a balloon opening the narrowed vessel, so called angioplasty, with or
without the additional deployment of a scaffold made of metal alloy or other material, so called stenting. Endovascular interventions
in the infrapopliteal vasculature may improve symptoms in patients with CLTI by re-establishing in-line blood flow to the foot.
Controversy remains as to whether a balloon should be used alone to open the vessel, or whether a stent should also be deployed.
Objectives
To determine the efficacy and safety of percutaneous transluminal angioplasty (PTA) alone versus PTA with stenting of infrapopliteal
arterial lesions (anterior tibial artery, posterior tibial artery, fibular artery (formerly known as peroneal artery), and common tibioperoneal
trunk) for patients with chronic limb-threatening ischaemia (CLTI).
Search methods
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase,
CINAHL, and AMED databases, as well as World Health Organization International Clinical Trials Registry Platform and Clinical-
Trials.gov trials registers to 25 June 2018. We applied no language restrictions.
Selection criteria
Weplanned to include randomised or quasi-randomised controlled trials comparing PTA versus PTA with a stent and including patients
aged 18 years or over with CLTI. We defined CLTI as Fontaine stage III (ischaemic rest pain) and IV (ischaemic ulcers or gangrene)
or consistent with Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss), and 6 (major tissue loss), with stenotic (> 50%
luminal loss) or occluded infrapopliteal artery, including tibiofibular trunk, anterior tibial artery, posterior tibial artery, and fibular
artery. We included all types of stents irrespective of design (e.g. bare-metal, drug-eluting, bio-absorbable).
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Data collection and analysis
Two review authors (CC-TH and GNCK) independently selected suitable trials, assessed trial quality, and extracted data. An additional
third review author (MLvD) assessed trial quality and, when necessary, acted as arbiter for study selection and data extraction. Outcomes
included technical success of the procedure, procedural complications, patency, major amputation, and mortality. We assessed the
quality of evidence using the GRADE approach.
Main results
We included in the review seven trials with 542 participants. One trial randomised limbs to undergo PTA alone or PTA with stent
placement, and the remaining studies randomised participants. Five trials with 476 participants show that the technical success rate was
greater in the stent group than in the angioplasty group (odds ratio (OR) 3.00, 95% confidence interval (CI) 1.14 to 7.93; 476 lesions;
5 studies; I² = 23%). Meta-analysis of three eligible trials with 456 participants did not show a clear difference in short-term (within
six months) patency between infrapopliteal arterial lesions treated with PTA and those treated with PTA and stenting (OR 0.88, 95%
CI 0.37 to 2.11; 456 lesions; 3 studies; I² = 77%). Results also did not show clear differences between treatment groups in procedure
complication rate (OR 0.87, 95% CI 0.01 to 53.60; 360 participants; 5 studies; I² = 85%), rate of major amputations at 12 months
(OR 1.34, 95% CI 0.56 to 3.22; 306 participants; 4 studies; I² = 0%), and rate of mortality at 12 months (OR 0.71, 95% CI 0.43
to 1.17; 497 participants; 6 studies; I² = 0%). Heterogeneity between studies was high for the outcomes procedure complications and
primary patency. The overall methodological quality of the trials included in this review was moderate due to selection and performance
bias. Studies used different regimens for pretreatment and post-treatment antiplatelet/anticoagulant medication. We downgraded the
certainty of the overall evidence for all outcomes by one level to moderate due to inconsistency of results across studies and large
confidence intervals (small numbers of trials and participants).
Authors’ conclusions
Trials show that the immediate technical success rate of restoring luminal patency is higher in the stent group but reveal no clear
differences in short-termpatency at six months between infrapopliteal arterial lesions treated with PTA with stenting versus those treated
with PTA without stenting. We ascertained no clear differences between groups in periprocedural complications, major amputation,
and mortality. However, use of different regimens for pretreatment and post-treatment antiplatelet/anticoagulant medication and the
duration of its use within and between trials may have influenced the outcomes. Limited currently available data suggest that high-
quality evidence is insufficient to show that PTA with stent insertion is superior to use of standard PTA alone without stenting for
treatment of infrapopliteal arterial lesions. Further studies should standardise the use of antiplatelets/anticoagulants before and after
the intervention to improve the comparability of the two treatments.
P L A I N L A N G U A G E S U M M A R Y
Angioplasty versus stenting for below-knee arterial disease in people with chronic limb-threatening ischaemia
Background
Chronic limb-threatening ischaemia (CLTI) is a manifestation of peripheral arterial disease that occurs as chronic ischaemic rest pain
or ischaemic skin lesions, ulcers, or gangrene with symptoms present for longer than two weeks. The symptoms are a result of impaired
blood flow to the leg and the foot due to narrowing of the arteries by atherosclerosis. Atherosclerosis is a disease of the arteries caused
by a buildup of plaque composed of fat, cholesterol, calcium, and other substances in the blood; over time, the plaque narrows the
artery. Patients can have narrowing of the artery in the thigh or below the knee. This review focusses on a subgroup of patients with
below-knee arterial disease (infrapopliteal arterial disease) who might benefit from an intervention that re-establishes blood flow by
inserting and inflating a balloon to re-open the narrowed artery (percutaneous transluminal angioplasty). This can be performed with
or without additional placement of a stent (a scaffold made of metal alloy or other material). The types of stents used in this procedure
vary from a simple bare-metal stent to a stent coated with medication. However, it is not clear whether deploying stents after ballooning
in narrowed below-knee arteries (infrapopliteal arteries) provides any additional benefit for the patient.
Study characteristics and key results
We identified seven trials with a combined total of 542 participants comparing percutaneous transluminal angioplasty (PTA) alone
versus PTA with stent placement (current until June 2018). One trial randomised limbs to PTA alone or PTA with stent placement,
and the remaining studies randomised participants. Full analysis of five trials shows that the technical success rate of re-opening the
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narrowed artery was higher in the stent group than in the PTA group. However, we noted no clear differences in patency (opened vessel
remaining open) of the treated vessel at six months. The complication rate of the procedure, the number of major amputations at 12
months, and the number of deaths at 12 months also did not differ greatly between treatment groups.
Certainty of the evidence
The overall certainty of evidence provided by the trials included in this review was moderate. Trials differed in their methods. Two
studies reported poorly on the methods used to generate random numbers and to allocate participants to different groups. All studies
were unblinded. All included studies were rated as direct in their relevance to the review question. Overall, we downgraded the certainty
of evidence for all outcomes by one level to moderate due to inconsistency of results across studies and the small numbers of studies
and participants.
Conclusion
PTA with stent placement is better than PTA alone for restoring vessel patency immediately; however we found no clear difference
in short-term patency at six months between the two groups. Trials show no clear differences between groups in complications at
or around the time of the procedure, major amputation, and death. Currently available data suggest that high-certainty evidence is
insufficient to show that PTA with stent placement is superior to PTA alone for treatment of infrapopliteal arterial lesions. Further
studies should standardise the use of blood-thinning drugs (antiplatelets/anticoagulants) before and after both interventions to improve
the comparability of the two treatments.
3Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PTA compared with stent for infrapopliteal arterial lesions in chronic limb- threatening ischaemia
Patient or population: people with inf rapopliteal arterial lesions in chronic limb-threatening ischaemia
Setting: hospital and outpat ient follow-up
Intervention: stent
Comparison: PTA
Outcomes Relative effect
(95% CI)
Anticipated absolute effects* (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
PTA Stent Difference
Technical success ITT
No. of limbs: 476
(5 RCTs)
OR 3.00
(1.14 to 7.93)
Study populat ion ⊕⊕⊕©
MODERATEa
93.3% 97.6%
(94.0 to 99.1)
4.4%more
(0.8 more to 5.8 more)
Technical success TA
No. of limbs: 474
(5 RCTs)
OR 2.78
(1.04 to 7.41)
Study populat ion ⊕⊕⊕©
MODERATEa
93.7% 97.6%
(93.9 to 99.1)
4.0%more
(0.2 more to 5.4 more)
Procedural complica-
t ions ITT
No. of part icipants: 360
(5 RCTs)
OR 0.87
(0.01 to 53.60)
Study populat ion ⊕⊕⊕©
MODERATEa
7.4% 6.5%
(0.1 to 81.1)
0.9% fewer
(7.3 fewer to 73.7 more)
Procedural complica-
t ions TA
No. of part icipants: 359
(5 RCTs)
OR 0.84
(0.01 to 47.70)
Study populat ion ⊕⊕⊕©
MODERATEa
7.4% 6.3%
(0.1 to 79.3)
1.1% fewer
(7.4 fewer to 71.9 more)
Primary patency < 6
months ITT
No. of lesions: 456
(3 RCTs)
OR 0.88
(0.37 to 2.11)
Study populat ion ⊕⊕⊕©
MODERATEa
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33.3% 30.6%
(15.6 to 51.3)
2.8% fewer
(17.7 fewer to 18 more)
Primary patency < 6
months TA
No. of lesions: 309
(3 RCTs)
OR 0.97
(0.32 to 3.00)
Study populat ion ⊕⊕⊕©
MODERATEa
45.9% 45.2%
(21.4 to 71.8)
0.8% fewer
(24.6 fewer to 25.9
more)
Mortality TA
No. of part icipants: 487
(6 RCTs)
OR 0.70
(0.42 to 1.15)
Study populat ion ⊕⊕⊕©
MODERATEa
19.3% 14.3%
(9.1 to 21.5)
5% fewer
(10.2 fewer to 2.3 more)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ITT: intent ion-to-treat; OR: odds rat io; PTA: percutaneous transluminal angioplasty; RCT: randomised controlled trial; TA: treatment analysis
GRADE Working Group grades of evidence.
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by one level due to inconsistency of results across dif ferent studies and imprecision (small numbers and wide
conf idence intervals).
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B A C K G R O U N D
Description of the condition
Atherosclerosis is the most common cause of peripheral arterial
disease (PAD) of the lower extremities. Chronic limb-threatening
ischaemia (CLTI), also known as critical limb ischaemia (CLI),
is a manifestation of PAD that refers to the presence of chronic
ischaemic rest pain or ischaemic skin lesions, ulcers, or gangrene,
with symptoms present for longer than two weeks (Hirsch 2006;
Norgren 2007). The severity of the disease depends on the extent
of arterial stenosis and the availability of collateral circulation.
Objective tests that support the diagnosis of CLTI include ankle-
brachial index (ABI), toe systolic pressure, and transcutaneous
oxygen tension (Hirsch 2006; Norgren 2007). CLTI is listed as
stage III and IV in the Fontaine classification and as categories 4, 5,
and 6 in the Rutherford classification (Table 1). The incidence of
CLTI is between 500 and 1000 new cases every year in a European
or North American population of one million (Norgren 2007).
The diagnosis of CLTI is associated with a poor prognosis for both
amputation-free survival and overall survival (Norgren 2007). The
prognosis of a patient with CLTI one year after diagnosis is death
in 20%, and the major amputation rate varies from around 10%
to 40% (Dormandy 1999). Observational studies of patients with
CLTI who are not candidates for revascularisation suggest that
only about half of these patients will be alive without a major
amputation a year after the onset of CLTI (Holdsworth 1997;
Norgren 2007); some of them may still have rest pain, gangrene,
or ulcers. Approximately 25% will have died, and 25% will have
required a major amputation (Norgren 2007; Wolfe 1986).
Description of the intervention
Treatment for CLTI aims to relieve ischaemic pain, heal ischaemic
ulcers, prevent limb loss, improve quality of life, and prolong sur-
vival (Norgren 2007). Interventions for CLTI may include conser-
vative therapy, revascularisation, or amputation. Progressive gan-
grene, rapidly enlarging wounds, and continuous ischaemic rest
pain often mandate the need for intervention. Although infrain-
guinal bypass surgery remains the cornerstone of CLTI treatment,
not all patients are suitable candidates. Patients may lack a con-
duit or target, may be non-ambulatory, or may have an extensive
soft tissue infection overlying a bypass target. Most commonly,
patients have medical comorbidities that make them unacceptable
surgical candidates, given that the associated mortality rate is ap-
proximately 2% (Conte 2001).
How the intervention might work
Endovascular interventions in the infrapopliteal vasculature in-
volve additional challenges of small-calibre vessels andmore diffuse
atherosclerotic disease. Potential obstacles include early thrombo-
sis and late luminal loss due to intimal hyperplasia formation, as
well as complications of acute vessel occlusion, embolism, and
vessel perforation during the procedure. A meta-analysis of in-
frapopliteal percutaneous transluminal angioplasty (PTA) com-
pared to popliteal-to-distal vein bypass surgery shows that the
bypass graft had better primary and secondary patency, but that
limb salvage was comparable for the two treatments, suggesting
the potential of PTA for treating CLTI (Romiti 2008). Trials are
providing increasing evidence to support a recommendation for
morbid PTA patients with CLTI as a result of infrapopliteal artery
lesions, provided that in-line flow to the foot can be re-established
(Norgren2007).Controversy remains as towhether primary stent-
ing of infrapopliteal arteries should be performed in patients with
CLTI to improve outflow or to increase patency of proximal en-
dovascular interventions or bypass surgery. Currently, stenting is
often reserved as a bailout option in cases of flow-limiting dissec-
tion, residual stenosis, or elastic recoil.
Why it is important to do this review
Recent advancements in stent design and growing expertise of
interventionalists have made it possible to treat complex lesions
that were previously known to have inferior outcomes, includ-
ing long-segment lesions, those with eccentric calcification, un-
stable lesions, and occlusions. A variety of novel stent designs are
available, ranging from bare-metal, metal-absorbable, carbofilm-
coated, bio-absorbable stents to drug-eluting stents. In particu-
lar, the drug-eluting stent has demonstrated efficacy for inhibit-
ing neo-intimal hyperplasia in the coronary arteries, thereby re-
ducing repeat revascularisation procedures, as compared with the
standard bare-metal coronary stent (Morice 2002; Moses 2003;
Schofer 2003). Whether the efficacy of coronary technology can
be translated to the infrapopliteal vasculature remains to be de-
termined. We are interested to learn whether PTA with primary
stenting offers advantages in improving outcomes compared with
PTA alone. If sufficient data are available, this systematic review
will also compare different stent designs.
O B J E C T I V E S
To determine the efficacy and safety of percutaneous transluminal
angioplasty (PTA) alone versus PTA with stenting of infrapopliteal
arterial lesions (anterior tibial artery, posterior tibial artery, fibular
artery (formerly known as peroneal artery), and common tibioper-
oneal trunk) for patients with chronic limb-threatening ischaemia
(CLTI).
M E T H O D S
6Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Criteria for considering studies for this review
Types of studies
We included randomised or quasi-randomised controlled trials
comparing PTA devices versus PTA with a stent.Wemade the dis-
tinction between PTA with the primary intention of stent place-
ment versus PTA with stent placement as a secondary intention.
Quasi-randomised controlled trials use amethod of allocating par-
ticipants that is not truly random, for example, odd or even hos-
pital number or date of birth, or they use alternation techniques
to allocate treatment groups.
Types of participants
We included adults (aged 18 years or older) with chronic limb-
threatening ischaemia (CLTI). We defined CLTI as Fontaine stage
III (ischaemic rest pain) and IV (ischaemic ulcers or gangrene) or
consistent with Rutherford categories 4 (ischaemic rest pain), 5
(minor tissue loss), and 6 (major tissue loss), with stenotic (> 50%
luminal loss) or occluded infrapopliteal artery, including tibiofibu-
lar trunk, anterior tibial artery, posterior tibial artery, and fibular
artery. This review includes participants with type 1 and type 2
diabetes.
Types of interventions
• Intervention: PTA with stenting
• Comparison: PTA alone (with bailout stenting after
suboptimal or complicated PTA)
We included all types of stents, irrespective of design (e.g. bare-
metal, drug-eluting, bio-absorbable).
Atherectomy was not permitted in either group.
Types of outcome measures
Primary outcomes
• Technical success defined as absence of residual stenosis <
30% and absence of flow-limiting dissection on final catheter
angiogram
• Procedural complications, including death as a direct result
of the procedure, vascular injury requiring vascular repair by
surgical or non-surgical techniques, arterial dissection, major
bleeding, stroke, myocardial infarction (MI), renal failure,
retroperitoneal bleed, embolisation resulting in partial or total
arterial occlusion, unplanned tibial or pedal bypass, major
infection, compartment syndrome, acute renal failure, access site
infection, groin haematoma, pseudoaneurysm, and arteriovenous
fistula
• Primary patency defined as < 50% loss of luminal diameter
at the treated site (determined by computerised tomography
(CT) angiogram, magnetic resonance (MR) angiogram, or
Doppler ultrasound) without re-intervention in the interim
• Secondary patency reflecting the fate of initial and
subsequent PTA procedures combined, and determined by CT/
MR angiogram or Doppler ultrasound as either the absence of a
haemodynamically significant re-stenosis or > 50% re-stenosis
Secondary outcomes
• Major amputation
• Mortality
• Clinical outcome of the treated ischaemic leg based on
Rutherford or Fontaine classification
• Healed or persistent ulcers
• Ankle-brachial index (ABI) or toe-brachial index (TBI)
• Quality of life assessment
Search methods for identification of studies
We applied no language restrictions to the search.
Electronic searches
The Cochrane Vascular Information Specialist first searched the
following databases for relevant trials on 22 March 2017.
• Cochrane Vascular Specialised Register.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2), in the Cochrane Library, via the
Cochrane Register of Studies ( http://www.metaxis.com/
CRSWeb/Index.asp).
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Information Specialist also searched the
following trials registries on 22 March 2017 for details of ongoing
and unpublished studies, using the terms ’popliteal’ and ’stent’.
• ClinicalTrials.gov ( clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform ( who.int/trialsearch).
• International Standard Randomized Controlled Trials
Number ( ISRCTN) Register ( http://www.isrctn.com/).
The Cochrane Vascular Information Specialist subsequently con-
ducted systematic top-up searches of the following databases.
• Cochrane Vascular Specialised Register via the Cochrane
Register of Studies (CRS-Web) (searched from 1 January 2017
to 25 June 2018).
• Cochrane Central Register of Controlled Trials
(CENTRAL), in the Cochrane Library, via the Cochrane
Register of Studies Online (CRSO; 2018, Issue 5).
• MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE®
Daily, and Ovid MEDLINE®) (searched from 1 January 2017
to 25 June 2018).
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• Embase Ovid (searched from 1 January 2017 to 25 June
2018).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) Ebsco (searched from 1 January 2017 to 25 June
2018).
• Allied and Complementary Medicine Database (AMED)
Ovid (searched from 1 January 2017 to 25 June 2018).
The Information Specialist modelled search strategies for the listed
databases on the search strategy designed for CENTRAL. When
appropriate, review authors combined these strategies with adap-
tations of the highly sensitive search strategy designed byCochrane
for identifying randomised controlled trials (RCTs) and controlled
clinical trials (as described in the Cochrane Handbook for System-
atic Reviews of Interventions, Chapter 6; Lefevbre 2011). We have
provided search strategies for the major databases in Appendix 2.
The Information Specialist also performed top-up searches of the
following trials registries on 25 June 2018.
• World Health Organization International Clinical Trials
Registry Platform ( who.int/trialsearch).
• ClinicalTrials.gov ( clinicaltrials.gov).
Searching other resources
We also searched citations within identified studies.
Data collection and analysis
We identified all randomised or quasi-randomised trials that com-
pare PTAdevices versus PTAwith stenting of infrapopliteal arterial
lesions (anterior tibial artery, posterior tibial artery, fibular artery,
and common tibioperoneal trunk) for patients with chronic limb-
threatening ischaemia. We assessed outcome measures as follows:
outcomes concerning technical success, long-term occlusions, and
adverse events. We assessed the primary outcome measures tech-
nical success and procedural complications within 30 days of the
index intervention. We assessed the remaining outcome measures
at intervals up to three months, up to six months, up to one year,
and annually thereafter, when data were available. If researchers
reported different time points, we also considered these.
Selection of studies
Two review authors (CC-TH and GNCK) independently assessed
studies identified for inclusion in this review using the criteria
stated above. In the case of disagreement, a third review author
(MLvD) acted as arbiter.
Data extraction and management
Two review authors (CC-TH and GNCK) independently ex-
tracted data from the studies included in this review using a stan-
dard data extraction form. In cases of disagreement, a third review
author (MLvD) acted as arbiter.
Assessment of risk of bias in included studies
Three review authors (CC-TH, GNCK, and MLvD) assessed the
risk of bias for each study as described in the Cochrane Handbook
for Systematic Reviews of Interventions for each of the following
domains (Higgins 2011).
• Random sequence generation.
• Allocation concealment.
• Blinding (of participants, personnel, and outcome
assessors).
• Incomplete outcome data.
• Selective outcome reporting.
• Other sources of bias.
We expressed judgements for each ’Risk of bias’ domain as low,
high, or unclear risk of bias. If researchers described and used ap-
propriate and adequate methods, we assessed the risk as ’low’. We
assessed the risk of bias as ’high’ when available information de-
scribed or suggested inadequate methods (e.g. non-random meth-
ods of allocation). An ’unclear’ risk of bias indicates that study
authors provided insufficient information.
Measures of treatment effect
Whendealingwith dichotomous outcomemeasures, we calculated
a pooled estimate of the treatment effect for each outcome across
trials using the odds ratio (OR) (the odds of an outcome among
treatment-allocated participants to the corresponding odds among
control participants) and the 95% confidence interval (CI). For
continuous outcomes, we recorded either mean change from base-
line for each group or mean post-intervention values and standard
deviations for each group. When appropriate, we then calculated
a pooled estimate of treatment effect by calculating the mean dif-
ference and the 95% CI.
Unit of analysis issues
We did not include cross-over trials in this review because re-
searchers designated only a single treatment to each group. If treat-
ment by percutaneous transluminal angioplasty (PTA) is success-
ful, it is inappropriate to expose study participants to other forms
of intervention (i.e. stenting). We considered cluster-randomised
trials, but, as the unit of analysis is the patient, we planned tomake
adjustments for clustering in the final analysis according to guide-
lines provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
In case of randomisation at the level of the limb, we considered
outcome data for each limb separately. In case of randomisation
per patient, we adjusted for clustering when considering outcome
data per limb. As per guidance from the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), we conducted
the analysis at the same level as the allocation, using a summary
measurement from each cluster when individual participant data
were available.
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Dealing with missing data
To enable an intention-to-treat (ITT) analysis, we sought data on
the number of participants with each outcome event by allocated
treatment group, irrespective of compliance and whether or not
the participant was later thought to be ineligible or was otherwise
excluded from treatment or follow-up. Review authors requested
missing data from the original investigators, when necessary.
Assessment of heterogeneity
We assessed statistical heterogeneity in the meta-analysis using the
I² statistic and explored reasons for heterogeneity (Higgins 2011).
Thresholds for interpretation of I² can be misleading because the
importance of inconsistency depends on several factors. We used
the rough guide to interpretation as outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We considered a level of heterogeneity of 50% or greater as signif-
icant.
We planned to assess clinical heterogeneity by conducting sub-
group analyses to stratify available data (see Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
We planned to investigate publication bias (referring to the phe-
nomenon that studies with a positive outcome are more likely to
be published) by using funnel plots if we identified 10 or more
studies for inclusion in the review (Higgins 2011). We captured
selective reporting of outcomes under Assessment of risk of bias
in included studies.
Data synthesis
We planned to use a fixed-effect model in our analysis. In cases of
significant heterogeneity (I² > 50%), we pooled the data using a
random-effects model (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses with participants strat-
ified by the following factors, if we had included five or more stud-
ies in the meta-analysis.
• Age 18 to 65 years and 65 years or older.
• Gender.
• Type 1 or type 2 diabetes.
• Different stent designs: stents can be classified by the four
parameters proposed by Nelken 2004 according to method of
deployment, geometry, construction materials, and treated stents
(coated stents and drug-eluting stents) (Table 2).
• Severity and extent of disease based on the TransAtlantic
Inter-Society Consensus II classification.
Sensitivity analysis
We planned to undertake sensitivity analysis to explore the impact
of risk of bias on meta-analysis of the overall estimate of effect
by first entering only trials with adequate allocation concealment
and blinding, and then gradually adding trials with high(er) risk
of bias.
’Summary of findings’
Wepresented themain findings of the review concerning certainty
of evidence, magnitude of effect of the interventions examined,
and sum of available data for the outcomes technical success in-
tention-to-treat analysis (ITT) and treatment analysis (TA), pro-
cedural complications ITT and TA, primary patency less than six
months ITT and TA, andmortality TA in a ’Summary of findings’
table, according to theGRADEprinciples, as described byHiggins
2011 and Atkins 2004. We evaluated evidence based on risk of
bias of the included studies, inconsistency, indirectness and impre-
cision of the data, and publication bias. We used GRADEprofiler
( GRADEpro) software to assist in preparation of the ’Summary
of findings’ table ( www.gradepro.org).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Seven randomised controlled trials met the criteria for inclusion
(Bosiers 2009; Brodmann 2011; Rand 2006; Rand 2011; Randon
2010; Spreen 2016; Tepe 2010). All studies were performed at ter-
tiary hospitals or through multi-centre collaboration. The study
population consisted of patients with symptomatic chronic limb
ischaemia Fontaine stage III and IV (Rand 2006), Rutherford
stage 4 to 5 (Bosiers 2009; Rand 2011), Rutherford stage 4 to
6 (Brodmann 2011; Randon 2010; Spreen 2016), and Ruther-
ford stage 5 to 6 (Tepe 2010). Rand 2011 randomised limbs
for treatment, and all remaining trials randomised participants
but reported event rates at the level of arterial lesions or limbs.
Age, gender, and risk factors of participants in the included trials
were comparable. The stent material used in the stenting group
was variable between studies but can be separated into drug-elut-
ing stents - Spreen 2016 and Tepe 2010 - versus non-drug-elut-
ing stents - Bosiers 2009, Brodmann 2011, Rand 2006, Rand
2011, and Randon 2010. Types of non-drug-eluting stents used
in these trials also varied in terms of stent design and material: ab-
sorbable metal stent (Bosiers 2009), silicon-carbide coating stent
(Brodmann 2011), carbostent (Rand 2006; Rand 2011), and self-
expandable stent (Randon 2010). Also, use of dual antiplatelet
therapy varied between control and experimental groups in in-
dividual trials and between trials. See Characteristics of included
studies for further details.
Excluded studies
We excluded seven trials (Bosiers 2012; Bradbury 2010; Rastan
2011; Scheinert 2012; Schulte 2015; Siablis 2007; Siablis 2014).
Bosiers 2012 and Rastan 2011 compared two different stents.
Bradbury 2010 presented a description of severity and extent
of disease using the Bollinger angiogram scoring method and
the TransAtlantic Inter-Society Consensus II classification in the
BASIL trial. Scheinert 2012, Schulte 2015, and Siablis 2014 in-
cluded patients with symptomatic peripheral arterial disease and
Rutherford stage 3 to 5manifested in the infrapopliteal arterial ter-
ritory, whereas in this review, we planned to include only patients
with stage 4 disease and above. These studies did not provide data
on the subgroup of patients with stage 4 or above disease; there-
fore we excluded them from the review. Siablis 2007 performed
stenting as a bailout procedure for suboptimal angioplasty, and
outcomes reflected a comparison between two different types of
stents, which is not within the scope of this review.
See Characteristics of excluded studies.
Ongoing studies
We identified one ongoing study (NCT01644487).
See Characteristics of ongoing studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Four studies used computer-generated randomisation procedures
(Bosiers 2009; Brodmann 2011;Randon 2010; Spreen2016). The
others did not describe the generation process, and we classified
them as having high risk of selection bias (Rand 2006; Rand 2011;
Tepe 2010).
Five studies described concealment of allocation as using sealed
envelopes (Bosiers 2009; Brodmann 2011; Rand 2006; Randon
2010; Spreen 2016). Two studies did not describe the allocation
concealment process; we therefore classified them as having high
risk of bias for this criterion (Rand 2011; Tepe 2010).
Blinding
None of the included studies described blinding of participants
or doctors performing the intervention. Although blinding of the
treating doctor is not possible in this context, blinding of partici-
pants could have been considered. Given the potential impact on
the overall effect estimate associated with non-blinding, even if
this is not feasible in a given setting, we classified all studies as
having high risk of bias in this domain.
Blinding of outcome assessment is feasible in the context of the
studied interventions; however only two studies described blinding
of the person assessing outcomes (Rand 2006; Randon 2010). We
classified the remaining studies as having high risk of bias.
Incomplete outcome data
All included studies, except two (Brodmann 2011; Tepe 2010), ac-
counted for all participants randomised in the study. We therefore
classed these as having high risk of bias. Three studies performed
ITT analysis (Bosiers 2009; Rand 2011; Spreen 2016), one study
performed survival analysis (Rand 2006), and one study reported
no losses to follow-up (Randon 2010).
Selective reporting
All included studies reported on the outcomes they intended to
measure; we therefore classed them as having low risk of reporting
bias.
Other potential sources of bias
Conflicts of interest and funding
Bosiers 2009 was funded totally by BIOTRONIK AG, which was
responsible for administration andmonitoring of the study. There-
fore, we classed this study as having high risk in this domain. Rand
2011 also received funding from the manufacturer of stents, but
study authors described that they were completely in control of
data analysis and publication; therefore, we classified this study
as having low risk in this domain. Randon 2010 does not men-
tion any support or conflict of interest; we therefore classified it
as having unclear risk. Tepe 2010 mentioned that the study was
supported by Eli Lilly but did not explicitly mention the inde-
pendence of the research team; we therefore classified this study
as having high risk.
Comparability of participants in groups
In Brodmann 2011, the two intervention groups were not compa-
rable. This study was originally conceived as a multi-centre trial,
but it included participants fromonly one centre. Brodmann 2011
reported an imbalance in cardiovascular risk factors, with a higher
percentage of baseline cardiovascular risk factors in the stent group
than in the PTA group. This imbalance could reflect high risk of
bias. Rand 2006 described administration of clopidogrel only to
participants who received stents - not to participants who under-
went PTA alone. Study authors stated: “We also observed a higher
incidence of PTAs than stent applications per patient. This might
be due to a certain degree of investigator bias, as potentially one
balloon can be used for several lesions in contrast to the necessity
of one stent per lesion.” We therefore judged Rand 2006 to be at
unclear risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison PTA
compared with stent for infrapopliteal arterial lesions in chronic
limb-threatening ischaemia
Primary outcomes
Technical success
Technical success: ITT
The event rate for technical success is defined by success of treated
infrapopliteal arterial lesions, with the exception of two trials
(Brodmann 2011; Spreen 2016), which counted limbs - Spreen
2016 - and numbers of participants - Brodmann 2011 - respec-
tively. Although Spreen2016 provided data on participants, limbs,
and lesions, Spreen 2016 excluded several participants post ran-
domisation before they received the allocated treatment. There-
fore, we report technical success in the ITT analysis with the limb
as the unit of analysis. We included in the meta-analysis five trials
with a total of 476 lesions (Bosiers 2009; Rand 2006; Rand 2011;
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Randon 2010; Tepe 2010). The primary success rate was higher
among stented lesions (odds ratio (OR) 3.00, 95% confidence in-
terval (CI) 1.14 to 7.93; P = 0.03; 5 studies; I² = 23%; moderate-
certainty evidence). Research results are heavily weighted by one
trial in which seven PTA without stenting group participants (7/
57) with 11 lesions (11/75) crossed over to the PTA with stenting
arm due to dissection in at least one of the lesions and, in the
case of one participant, due to significant residual stenosis (Bosiers
2009). See Analysis 1.1.
In Brodmann 2011, the procedure was successful in 94% (31/
33) of participants treated with PTA alone and in 100% (21/21)
of those treated with PTA with stents. Two participants in the
PTA alone group encountered extended dissections in the treated
vessels requiring secondary stent placement.
Spreen 2016 provided data on participants, limbs, and numbers of
lesions; however investigators excluded several participants from
the study post randomisation. Therefore, we report technical suc-
cess in the ITT analysis with limb as the unit of analysis. Spreen
2016 randomised 69 limbs to the PTA alone group and 75 limbs
to the PTA with stent group. This study excluded three partic-
ipants/three limbs post randomisation to the PTA alone group
and one participant/one limb post randomisation to the PTA with
stent group. Spreen 2016 treated 14 limbs in the PTA alone group
with a bailout stent. Seven participants in the PTA alone group
had > 50% stenosis or occlusion, and six in the stent group had >
50% stenosis or occlusion. Hence the success rate was 65% (45/
69) in the PTA alone group and 91% (68/75) in the PTA with
stent group.
Technical success: TA
The event rate for technical success is defined by success of treated
infrapopliteal arterial lesions, with the exception of two trials
(Brodmann 2011; Spreen 2016), which counted limbs - Spreen
2016 - and numbers of participants - Brodmann 2011 - respec-
tively. Although Spreen2016 provided data on participants, limbs,
and lesions, study authors did not specify the number of lesions
in the PTA alone group requiring bailout stenting. Therefore, we
report technical success in the treatment analysis with the limb as
the unit of analysis.
We included five trials with a total of 474 lesions reporting this
outcome (Bosiers 2009; Rand 2006; Rand 2011; Randon 2010;
Tepe 2010). The primary success rate was higher among stented
lesions (OR 2.78, 95% CI 1.04 to 7.41; P = 0.04; 5 studies; I² =
15%; moderate-certainty evidence). See Analysis 1.2.
Brodmann 2011 reported a technical success rate of 94% (31/33)
in the PTA alone group and 100% (21/21) in the PTA with stent-
ing group. Two participants from the PTA alone group crossed
over to the stent group due to arterial dissection of the treated
vessels requiring stent placement.
Spreen 2016 randomised 69 limbs to the PTA alone group and 75
limbs to the PTA with stent group. Investigators excluded three
participants/three limbs post randomisation to the PTA alone
group and one participant/one limb post randomisation to the
PTA with stent group. They treated 14 limbs in the PTA group
with a bailout stent. Seven participants in the PTA alone group
had > 50% stenosis or occlusion, and six in the PTA plus stent
group had > 50% stenosis or occlusion. Hence the success rate
was 65% (45/69) in the PTA alone group and 90% (68/75) in the
PTA with stent group.
Procedural complications
Procedural complications: ITT
Procedural complications are reported per individual participant.
We analysed five trials with 360 participants (Bosiers 2009;
Brodmann 2011; Rand 2011; Randon 2010; Tepe 2010). Bosiers
2009, Rand 2011, and Tepe 2010 reported no procedural com-
plications and found no clear differences between participants in
PTA alone and PTA with stenting groups (OR 0.87, 95% CI 0.01
to 53.60; 360 participants; 5 studies; I² = 85%;moderate-certainty
evidence). See Analysis 1.3.
Spreen 2016 reported procedural complications per limb: 22%
(15/69 limbs) in the PTA group and 27% (20/75 limbs) in the
stenting group. These complications included haematoma, mate-
rial dysfunction, acute thrombosis, distal embolus, and pseudoa-
neurysm. Serious adverse events occurred in 22% (15/69 limbs)
in the PTA alone group and in 20% (15/75 limbs) in the PTA
with stenting group. These included gastrointestinal bleeding, is-
chaemic cerebral event and cerebral haemorrhage, pneumonia, car-
diac disease, renal failure, and non-CLTI-related infection. Spreen
2016 reported that overall, the incidence of periprocedural com-
plications and serious adverse events did not differ significantly
between the two groups.
Rand 2006 reported one puncture site haematoma and one case
of post-procedural sepsis but did not specify in which group these
complications occurred.
Procedural complications: TA
Procedural complications are reported per individual participant.
We analysed five trials with 359 participants (Bosiers 2009;
Brodmann 2011; Rand 2011; Randon 2010; Tepe 2010). We
found no clear difference between participants in PTA alone and
PTA with stenting groups (OR 0.84, 95% CI 0.01 to 47.70;
moderate-certainty evidence). Heterogeneity was significant (I² =
84%). Bosiers 2009, Rand 2011, and Tepe 2010 reported no cases
of procedural complications. See Analysis 1.4.
Spreen 2016 reported procedural complications per limb: 23%
(15/66 limbs) in the PTA group and 27% (20/74 limbs) in the
stenting group. Serious adverse events occurred in 23% (15/66
limbs) in the PTA group and in 20% (15/74 limbs) in the stenting
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group.We have reported details of these complications and serious
adverse events in the section above.
Primary patency at six months
Primary patency at six months: ITT
We included three trials with a total of 456 lesions (Bosiers 2009;
Rand 2006; Spreen 2016). We found no clear differences between
PTA alone and PTA with stenting groups (OR 0.88, 95% CI
0.37 to 2.11; moderate-certainty evidence). Heterogeneity was
significant (I² = 77%). See Analysis 1.5.
Randon 2010 reported patency outcomes with the participant as
the unit of measurement, and we did not include this study in the
meta-analysis. Cumulative primary and secondary patency rates
were 76% and 85% at six months for the PTA alone group, and
80% and 91% at six months for the PTA with stenting group.
Randon 2010 reported no significant differences in primary or
secondary patency between the two treatment groups.
Primary patency at six months: TA
We included three trials with a total of 309 lesions (Bosiers 2009;
Rand 2006; Spreen 2016). We found no clear differences between
participants in PTA alone and PTA with stenting groups (OR
0.97, 95% CI 0.32 to 3.00; moderate-certainty evidence). Het-
erogeneity was significant (I² = 82%). See Analysis 1.6.
Brodmann 2011 reported primary patency per participant at six
months, with 60.7% patency in the PTA alone group and 52.6%
in the PTA with stent group.
Primary patency at 12 months: ITT
Most trials did not report data on patency of treated lesions beyond
six months.
Brodmann 2011 reported primary patency per participant at 12
months, with 48.1% patency in the PTA alone group and 35.3%
in the PTA with stent group.
Rand 2011 reported patency results at nine months: the minimal
lumen diameter after nine months was not significantly different
between the PTA alone group and the PTA with stent group. The
percentage of residual diameter stenosis also was not significantly
different: 43% in the PTA alone group versus 39% in the PTA
with stent group. In addition, binary re-stenosis for a 50% and a
70% threshold was not significantly different: 34.6% in the PTA
alone group versus 23.8% in the PTAwith stent group, and 15.4%
in the PTA alone group versus 9.5% in the PTA with stent group,
respectively.
Randon 2010 defined primary patency as clinical primary patency:
this means freedom from re-stenosis; occlusion with recurrence
of ischaemic rest pain or recurrence of ulceration, leading to redo
angioplasty; bypass surgery; or major amputation. Randon 2010
defined secondary patency as freedom from redo angioplasty until
recurrence of symptoms. Randon 2010 reported that cumulative
primary and secondary patency rates for the PTA alone group
were 66% and 79.5% at 12 months, and primary and secondary
patency rates for the PTA with stenting group were 56% and 64%
at 12 months. Results show no clear differences in primary or
secondary patency between the two groups.
Secondary patency
Two trials reported secondary patency after repeat angioplasty for
re-stenosis or recurrence of symptoms (Randon 2010; Brodmann
2011). In Randon 2010, cumulative secondary patency rates for
the PTA alone group were 85% at six months and 79.5% at 12
months. Secondary patency rates for the PTA with stenting group
were 91% at six months and 64% at 12 months. Results show no
clear differences in primary or secondary patency between the two
treatment groups. Brodmann 2011 also reported on secondary
patency, with no reported differences between PTA alone and PTA
with stenting groups at six months, but at 12 months, patency
rates were 70.4% in the PTA alone group and 52.9% in the PTA
with stent group.
Secondary outcomes
Major amputations < 12 months after the index intervention
Major amputations < 12 months after the index intervention:
ITT
We analysed four trials with 306 participants (Bosiers 2009; Rand
2011; Randon 2010; Tepe 2010); we found no clear differences
in major amputations between PTA alone and PTA with stenting
groups (OR 1.34, 95% CI 0.56 to 3.22).
Spreen 2016 reported a major amputation rate of 38% (13/69
limbs) in the PTA alone group and 20% (8/75 limbs) in the PTA
with stenting group. Brodmann 2011 reportedminor amputations
only. Rand 2006 reported one major amputation in a participant
undergoing stent application.
Major amputations < 12 months after the index intervention:
TA
We analysed four trials with 252 participants (Bosiers 2009; Rand
2011; Randon 2010; Tepe 2010); we found no clear differences
in major amputations between PTA alone and PTA with stenting
groups (OR 1.41, 95% CI 0.59 to 3.40).
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Mortality within 12 months after the index intervention
Mortality within 12 months after the index intervention: ITT
We analysed six trials with 497 participants (Bosiers 2009;
Brodmann 2011; Rand 2011; Randon 2010; Spreen 2016; Tepe
2010); we noted no clear differences in mortality between PTA
alone and PTA with stenting groups (OR 0.71, 95% CI 0.43 to
1.17; moderate-certainty evidence).
Rand 2006 reported one death but did not specify the treatment
group in which this occurred.
Mortality within 12 months after the index intervention: TA
We analysed six trials with 487 participants (Bosiers 2009;
Brodmann 2011; Rand 2011; Randon 2010; Spreen 2016; Tepe
2010); we found no clear differences between participants in PTA
alone and PTA with stenting groups (OR 0.7, 95% CI 0.42 to
1.15).
Clinical outcome of the treated ischaemic leg using the
Rutherford or Fontaine classification at < six months and at
< 12 months
Brodmann 2011 reported improvement by at least one Rutherford
category in a total of 33 (75.0%) participants at 12 months: 22
(81.5%) in the PTA alone group and 11 (64.7%) in the PTA with
stent group (P value as reported by study authors = NS).
Bosiers 2009 reported six-month clinical status of participants by
the evolution of the Rutherford category. Investigators reported
improvement by at least one Rutherford category in 65.9% (27/
41) in the PTA alone group and in 69.2% (27/39) in the PTA with
stent group with no statistically significant differences between
groups by either ITT or treatment analysis.
In Rand 2011, clinical results based on the American Heart Asso-
ciation Clinical Improvement Score show clinical improvement at
three months in 20 of 32 participants (62.5%) in the PTA alone
group. Twelve of the 32 participants (37.5%) had clinical wors-
ening or remained stable. The PTA with stent group shows clin-
ical improvement in 27 of 33 participants (81.8%) and clinically
worsening or stable disease in six participants (18.2%). At nine
months’ follow-up, the PTA alone group included 24 participants
and the PTA with stent group included 19 participants. At nine
months, 14 of 24 participants (58.3%) in the PTA alone group
show improved clinical status, and the remaining 10 participants
(41.7%) show clinical worsening or remain stable. The PTA with
stent group shows nine of 19 participants (47.4%) with clinical
improvement and 10 of 19 participants (52.6%) with clinically
worsening or stable disease.
The remaining included studies did not report on the clinical out-
come of the treated ischaemic leg using the Rutherford or Fontaine
classification at < six months and at < 12 months.
Healed or persistent ulcers at < six months’ and at < 12
months’ follow-up
Brodmann 2011 reported that complete ulcer healing at 12
months was evident in 21 (63.6%) participants: 16 (80.0%)
treated with PTA alone and five (38.5%) treated with PTA with
stenting becameulcer free (P as reported by study authors = 0.006).
Tepe 2010 described general reduction in mean ulcer size (cm²) in
both PTA alone and PTA with stent groups without performing
statistical analysis. In the PTA alone group (PTA with or without
abciximab),meanulcer sizeswere 8.4 cm² and15 cm², respectively,
at baseline; 2.9 cm² and 13 cm² at two months; and 0.63 cm² and
1 cm² at nine months. In the PTA with stent group (bare-metal
stent and drug-eluting stent), mean ulcer sizes were 48.7 cm² and
11.6 cm², respectively, at baseline; 39.1 cm² and 5.3 cm² at two
months; and 32.1 cm² and 2.9 cm² at nine months.
The remaining included studies did not report on healed or per-
sistent ulcers at < six months’ and < 12 months’ follow-up.
Ankle-brachial index (ABI) or toe-brachial index (TBI) at <
six months’ and < 12 months’ follow-up
Rand 2011 reported that ABIs at three months were 0.7 ± 0.3 for
the PTA alone group and 0.9 ± 0.1 for the PTA with stent group
(no significant difference). At nine months, they were 0.8 ± 0.3
for the PTA alone group and 0.8 ± 0.1 for the PTA with stent
group (no significant differences).
Spreen 2016 reported significant improvement in mean ABIs and
toe pressure after six months and after 12 months among survivors
of both treatment groups compared with baseline (P ≤ 0.005).
Spreen 2016 also reported that these improvements were compa-
rable in both treatment groups.
Bosiers 2009 reported that ABIs at baseline were 0.7 ± 0.3 for the
PTA alone group and 0.8 ± 0.5 for the PTA with stent group. At 24
hours after endovascular treatment, ABIs increased significantly to
1.0 ± 0.2 in the PTA alone group and 1.0 ± 0.4 in the PTA with
stent group. At six months, they were 0.9 ± 0.3 for the PTA alone
group and 0.9 ± 0.4 for the PTA with stent group (no significant
differences).
Quality of life assessment
Included trials did not perform this assessment.
Long-term follow-up
Very limited follow-up data are available beyond the 12-month
period. Spreen 2017 published long-term clinical outcomes of the
PADI trial (Spreen 2016). Unfortunately, Spreen 2017 did not
separate out participants who had only PTA and those who had
PTA with bailout bare-metal stent. Nevertheless, limited available
results show higher primary patency rates after the drug-eluting
stent compared with PTA with or without a bailout bare-metal
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stent at one, three, and four years’ follow-up. The five-year major
amputation rate was lower in the drug-eluting stent group than in
the PTA with or without bailout bare-metal stent group (19.3% vs
34.0%; P = 0.091). Overall survival rates were comparable (Spreen
2017).
Subgroup analyses, sensitivity analyses, and assessment of
publication bias
We did not perform subgroup analyses, as included trials did not
provide data specific for age, gender, diabetes status, or TransAt-
lantic Inter-Society Consensus II classification. However, we did
perform sensitivity analysis by removing studies deemed at high
risk of bias, such as Rand 2011 and Tepe 2010. However, this did
not change the conclusion for relevant outcomes.
We did not perform subgroup analysis for different types of stents.
Although stents used in the trial can be broadly separated into
drug-eluting stents - Spreen 2016 and Tepe 2010 - and non-drug-
eluting stents - Bosiers 2009, Brodmann 2011, Rand 2006, Rand
2011, and Randon 2010 - the types of non-drug-eluting stents
used vary significantly in material and design, and included ab-
sorbable metal stents (Bosiers 2009), silicon-carbide coating stents
(Brodmann 2011), carbostents (Rand 2006; Rand 2011), and self-
expandable stents (Randon 2010). Pooling these varied types of
non-drug-eluting stents into a single group was not considered ap-
propriate. Last, the small number of participants included in these
trials limits the ability of researchers to detect subgroup effects.
D I S C U S S I O N
Summary of main results
Our review shows that technical success is significantly greater in
the percutaneous transluminal angioplasty (PTA) with stent group
than in the PTA alone group. This may due in part to the use of
stenting as a bailout solution to arterial dissection, which is a com-
plication of PTA, as demonstrated in the heavily weighted Bosiers
2012 trial. Overall, we found no clear differences in complication
rates between PTA with stent and PTA alone groups, but hetero-
geneity between studies was significant. Similarly, we observed no
clear differences in short-term patency at six months between the
two treatment groups. Very few trials reported longer-term follow-
up (up to 12 months), and only Brodmann 2011, Rand 2011,
and Randon 2010 provide data on patency at 12 months. These
studies do not show a clear difference in patency between the two
treatment groups. Rates of major amputation and mortality were
not significantly different between the two treatment groups. We
performed sensitivity analysis by removing studies at high risk of
bias, such as Rand 2011 and Tepe 2010, but this analysis did not
alter our overall conclusions.
Overall completeness and applicability of
evidence
Most of the trials included in this review provided only short-
term follow-up of up to six months. Only three trials provided
follow-up data on long-term patency extending to 12 months.
Although long-term durability of the stent and long-term patency
of the treated lesion remain unknown due to the inherent high
morbidity and mortality of cardiovascular risk factors associated
with chronic limb-threatening ischaemia, the benefit of achieving
short-term vessel patencymay still be clinically relevant. Last, trials
show inconsistency in the use of periprocedural anticoagulation
and the use of oral anticoagulation or antiplatelet medications
post treatment. The PTA with stenting group was more likely to
receive antiplatelet medications post treatment, as clinicians have
the added burden of preventing stent re-stenosis in these patients
compared to those treated with PTA alone. These confounding
variables could influence the outcome of patency.
Not all studies reported on all outcomes, and pooled analysis was
not always possible, for example, for secondary patency.
Quality of the evidence
The overall methodological quality of the included studies was
moderate. Studies generally reported poorly on methods used to
allocate participants to different study groups. All studies were un-
blinded, but this can be justified by the nature of the intervention,
as it is not possible to ensure blinding of doctors performing the
angioplasty or placing the stent. Theoretically, it could be possible
to blind participants or outcome assessors to the intervention per-
formed; however, none of the included studies described blind-
ing of participants and/or outcome assessors. Most trials poorly
reported conflicts of interest and details of financial support.
Outcomes of the included studies are relevant and are generalisable
to the clinical population, hence we found no serious indirectness.
We considered moderate to severe heterogeneity as inconsistency
of results, and we found serious inconsistency for outcomes con-
cerning technical success rate, complications, and six-month pa-
tency. We therefore downgraded the certainty of evidence by one
level to moderate for all outcomes due to inconsistency of results
across different studies and imprecision (small numbers and wide
confidence intervals).
A major confounder is inconsistency in the use of anticoagulation
and antiplatelet medications between PTA alone and PTA with
stenting groups, as well as between trials. Established evidence sug-
gests that patients with peripheral vascular disease treated by an-
gioplasty or stenting would benefit from receiving aspirin at a dose
of 50 mg to 300 mg daily, started before angioplasty or stenting
and continued for at least two years or given lifelong (Robertson
2012). On the other hand, proven benefit of clopidogrel or dual
antiplatelet or anticoagulant use in patients undergoing peripheral
vascular interventions has not been definitively established.
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Last, only Rand 2011 randomised limbs; all other included trials
randomised at the participant level but reported outcomes at the
level of arterial lesions or limbs. Such trials do not adjust for the
non-independence between arterial lesionswithin the same patient
(e.g. by applying cluster analysis). In our meta-analysis, we did not
use generalised estimated equations, as individual participant data
were not available to us. Therefore, wemay have overestimated the
estimated effects of treatments. However, given that the number
of participants with bilateral lesions is small, we assume that the
unit of analysis error does not have a major impact on the overall
result. Please refer to Characteristics of included studies for details
on bilateral lesions.
Potential biases in the review process
TheCochrane Vascular Information Specialisist searchedmultiple
databases and trials registers to identify trials for this review. The
review authors also independently searched references lists in other
studies and reviews, and it is likely that we have included in this
review all major trials on this subject matter.However, it is possible
that despite extensive searches in multiple databases, we may have
missed relevant studies for inclusion.
Two review authors independently performed all data selection
and extraction with consultation from a third review author to
ensure completeness and to exclude bias and error.
Different trials reported outcomes at different time intervals, and
to allow meta-analysis, we have pooled data from various time
frames within the prespecified periods of six months and 12
months. For example, researchers assessed primary vessel patency
at two, three, six, nine, and 12 months. We pooled the data into
two separate time frames - six months and 12 months. Similar-
ily, we assessed cumulative mortality and major amputation for
all trials at 12 months. This may have created bias in favour of
studies reporting outcomes at earlier time points, as it is possible
that adverse or unintended outcomes might have occurred later
and would not have been captured.
Agreements and disagreements with other
studies or reviews
We identified an existing systematic review and meta-analysis that
compared the role of drug-eluting stents versus angioplasty or
bare-metal stents in infrapopliteal arterial disease (Fusaro 2013).
This review identified five trials, but four of these trials compared
drug-eluting stents versus bare-metal stents, and this comparison
is not relevant to the objective of our review. The only trial that is
relevant to our objective is Tepe 2010, which we included in our
analysis.
The Yang 2014 review included 16 studies, nine of which were
retrospective studies, four prospective non-randomised studies,
and three randomised controlled trials (RCTs). Two of the in-
cluded RCTs are not relevant to our topic, as investigators com-
pared drug-eluting stents versus bare-metal stents (Bosiers 2012;
Rastan 2011). We identified one of the included RCTs through
our search, but we excluded it from our analysis (Scheinert 2012).
This trial included Rutherford stage 3 to 5 infrapopliteal arterial
disease without providing data for stages 2, 4, and 5 separately.
In our review, we planned to include only patients with stage 4
disease and above.
Another systematic review and meta-analysis shows close resem-
blance to our review (Wu 2014).Wu2014 included six prospective
RCTs (Bosiers 2009; Brodmann 2011; Rand 2006; Rand 2011;
Randon 2010; Scheinert 2012). Our review includes these tri-
als and has added two other trials (Spreen 2016; Tepe 2010), al-
though we excluded Scheinert 2012 for the reasons mentioned
above. Outcomes assessed in the Wu 2014 review include imme-
diate technical success, primary and secondary patency, limb sal-
vage, and patient survival (assessed at six-month and 12-month
intervals). However, Wu 2014 did not include procedural com-
plications in its analysis and found that immediate technical suc-
cess was greater in the PTA with stent group (96.2%) than in the
PTA alone group (93.3%), but this finding was not statistically
significant (odds ratio (OR) 0.59, 95% confidence interval (CI)
0.24 to 1.47). In contrast, we found a difference in the immediate
technical success rate. The difference in conclusions between these
reviews is likely to be influenced by differences among included
trials. In relation to patency at six months, Wu 2014 analysed four
studies and showed no significant differences between the PTA
alone group of 73.4% and the PTA with stent group of 75.9%
(OR 0.94, 95% CI 0.48 to 1.8) (Bosiers 2009; Rand 2006; Rand
2011; Randon 2010). We analysed Bosiers 2009, Rand 2006, and
Spreen 2016 and revealed a similar result of no clear differences in
primary patency at six months. In our review, we analysed cumu-
lative mortality at 12 months, whereas Wu 2014 analysed patient
survival at six months and 12 months; both reviews found no clear
differences between the two treatment groups.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our meta-analysis of five trials (four trials with estimable data)
including participants with chronic limb-threatening ischaemia
(CLTI) shows a greater technical success rate in the PTA with stent
group than in the PTA alone group but no clear differences in
short-term patency (at six months) between infrapopliteal arte-
rial lesions treated with PTA alone and those treated with PTA in
combination with stenting. We found no clear differences in com-
plication rates between PTA and PTA with stent groups. Overall,
the 12-month major amputation rate and the mortality rate are
not clearly different between PTA and PTA with stent groups.
However, the use of different regimens for pretreatment and post-
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treatment antiplatelet medication, such as clopidogrel, and the
duration of its use within and between trials may have influenced
the outcome. Based on limited currently available data and on the
results of this meta-analysis, high-quality evidence is insufficient
to suggest that stent insertion is superior to standard PTA alone
without stenting for treatment of infrapopliteal arterial lesions.
Stent insertion could be reserved for use as a ’bailout’ procedure
when arterial dissection is encountered.
Implications for research
More consistent trial reporting is needed on both randomisation
of limbs as the unit of analysis and use of antiplatelet and antico-
agulant treatment before and after the intervention. Future trials
should use limbs as the unit of allocation and reporting, and use
of antiplatelet and anticoagulant treatment before and after the
intervention should be standardised in upcoming trials. Future tri-
als also must implement standardised reporting of outcomes and
time intervals for re-assessment; this will allow better comparison
of data between trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bosiers 2009
Methods Country: Absorbable Metal Stents (AMS) INSIGHT investigators (13 clinical sites in
Austria, Belgium, Germany, and The Netherlands)
Setting: multi-centre tertiary hospital
Study design: RCT
Level of randomisation: participant
Participants No. of participants randomised: 57 were randomised to the percutaneous transluminal
angioplasty (PTA) group, and 60 to the AMS group. In total, 149 lesions were treated in
117 participants, which resulted in a total of 74 lesions in the AMS arm and 75 lesions
in the PTA control arm
Exclusions post randomisation: none
Shifted to another treatment arm: if stenosis persisted to be > 50% or a flow-limiting
dissection occurred, the participant underwent implantation of the AMS study stent and
ended up in the cross-over group. Seven PTA group participants (7/57) with 11 lesions
(11/75) crossed over to the other treatment arm due to dissections in at least 1 of the
lesions and, in the case of 1 participant, due to significant residual stenosis
Number of participants evaluated: 7 PTA group participants (7/57) with 11 lesions
(11/75) crossed over to the other treatment arm due to dissection in at least 1 of the
lesions and, in the case of 1 patient, due to significant residual stenosis. These participants
were included in the PTA + AMS group, which was not considered in the on-treatment
data analysis performed by study authors. One participant randomised for stenting (1/
60) with a double lesion (2/74) underwent implantation of a non-study stent (self-
expanding) due to severe tortuosity of the iliac artery. Therefore, this participant was
not considered in the on-treatment analysis performed by study authors. The final on-
treatment cohort consisted of 50 participants with 64 lesions treated with PTA only
and 59 participants with 72 lesions who underwent implantation of the study stent.
Therefore, according to the study authors, ITT technical success, which was based on
visual assessment, was achieved in 60 of 60 participants in the AMS group (100%),
and in 55 of 57 participants in the PTA group (96.4%). For one PTA lesion, data on
technical success were not provided by the investigator, and this participant’s treatment
was considered a non-success
Age (mean), years: PTA only 73.1, AMS 74.7
Gender: PTA group: 41 male/16 female, AMS stent group: 31 male/29 female
Inclusion criteria: stenotic (> 50%) or occlusive atherosclerotic disease of the in-
frapopliteal arteries, length of lesion < 15mm (< 1 stent length), reference vessel diameter
3.0 mm to 3.5 mm, maximum of 2 lesions in 1 infrapopliteal vessel treated in the study
or in 2 vessels of 2 different legs, symptomatic critical limb ischaemia (Rutherford 4 and
5), patient ≥ 50 years of age, life expectancy > 6 months, no child-bearing potential or
negative serum pregnancy test within 7 days of the index procedure, participant willing
and able to return at appropriate follow-up times for the duration of the study, patient
provision of written patient informed consent that is approved by the ethics committee
Exclusion criteria: patient refusal of treatment; reference segment diameter not suitable
for available stent design; length of lesion requiring more than 1 stent implantation;
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previously implanted stent(s) or PTA at the same lesion site; lesion lying within or
adjacent to an aneurysm; inflow-limiting arterial lesions left untreated; known allergy
to heparin, aspirin, or other anticoagulant/antiplatelet therapies or bleeding diatheses,
or unable or unwilling to tolerate such therapies; taking phenprocoumon (Marcumar);
history of prior life-threatening contrast medium reaction; currently enrolled in another
investigational device or drug trial; currently breastfeeding, pregnant, or intending to
become pregnant; mentally ill or retarded; liable for military or civilian service
Interventions AMS stenting group:
• Target lesion was pre-dilated with the Pleon Explorer balloon mandatory in this
study. After dilatation, the stenosed area was treated with 1 AMS implant. Post-
dilatation was allowed at the discretion of the physician, for cases where angiographic
control revealed suboptimal apposition of the AMS to the vessel wall or flow-limiting
residual stenosis
PTA group (control):
• Pleon Explorer balloon
Medication:
• Clopidrogel saturation was obtained before the procedure
• Heparin was administered during the procedure according to standard practice
• Post-procedure antithrombotic regimen was that used according to the protocol
(clopidogrel 75 mg daily for 1 month and aspirin 75 to 300 mg daily lifelong)
Outcomes Primary outcomes:
• Absence of clinical complications at 1 month post procedure. Complications were
defined as major amputations or any cause of death. Major amputations were defined
as amputations at or above the ankle
• 6-month angiographic patency rate after PTA alone or PTA followed by AMS
implantation in patients with stenotic or occlusive atherosclerotic disease of the
infrapopliteal arteries. Patency was defined as the absence of a haemodynamically
significant re-stenosis (50%) documented by digital subtraction angiography and
confirmed by core-lab QVA
Secondary outcomes:
• Immediate angiographic technical success, which was defined in both therapy
groups as 30% final residual diameter stenosis of the target segment based on visual
assessment of the planned treatment area
• Late lumen loss (LLL) as diagnosed at 6-month angiographic control and defined
by the difference between in-stent minimal lumen diameter (MLD) post procedure
and MLD at follow-up measured by angiography
• Limb salvage rate, defined as lack of major amputations at different prescheduled
follow-up visits until 12 months after index intervention
• Primary patency rates at each visit as determined by colour flow Doppler
ultrasound (CFDU) and defined as the absence of a haemodynamically significant re-
stenosis (50%) derived from the ratio of peak systolic velocity (PSV) at the lesion
segment to that at the proximal part, a major amputation, or a TLR
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned
to either PTA or AMS implantation. The
randomization list was generated using
PROC PLAN of SAS (Statistical Analysis
Software)”
Allocation concealment (selection bias) Low risk Quote: “Sequentially numbered sealed en-
velopes contained information on the treat-
ment to be applied. The sealed envelopes
were opened only after the lesion was suc-
cessfully crossed with the guidewire, and
then patients were allocated either to stent
or to PTA alone”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk None
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary safety endpoint at 1 month re-
ported for 57/57 in the PTA group and for
59/60 in the AMS group
Primary efficacy endpoint at 6 months re-
ported for 40/57 in the PTA group and for
37/60 in the AMS group
7 participants in the PTA group crossed
over to other treatment (included in PTA
+ AMS group for on-treatment analysis)
1 participant in the AMS group underwent
implantation of a non-study stent (not in-
cluded in on-treatment analysis)
Sudy authors provide on-treatment and
ITT analyses
Selective reporting (reporting bias) Low risk None
Other bias High risk Quote: “The devices used in the study were
the first-generationAMS and the PleonEx-
plorer angioplasty balloon catheter, both
developed by BIOTRONIK AG (Switzer-
land). The sponsor, BIOTRONIK AG,
funded the total study costs and was re-
sponsible for the study administration and
monitoring of the study”
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Methods Country: Austria
Setting: monocentre university hospital
Study design: RCT
Level of randomisation: participant
Participants No. of participants randomised: 54 patients were randomised to primary stenting
(balloon expandable stent) or PTA alone
Exclusions post randomisation: not mentioned; assumed none
Shifted to another arm: 2 participants in PTA group with dissection in treated vessels
required secondary stent, and total of 3 stents were placed
Number of participants evaluated: overall 54 participants were included, with 33
assigned to the PTA group and 21 to the stent group
Age (mean), years: 74.9 PTA, 68.9 stent
Gender: 13/33 males PTA, 12/21 males stent
Inclusion criteria: critical limb ischaemia, with Rutherford classification 4 to 6; lesion
criteria characterised as the following: isolated stenoses > 70%, sequential stenoses up to
cumulative length 12 cm, or total occlusion of crural arteries with maximum length 12
cm; target vessel must be a distal runoff vessel; written informed consent; life expectancy
≥ 12 months
Exclusion criteria: endovascular procedure at the target vessel within the last 3 months;
refused informed consent; known allergy against clopidogrel or aspirin; indication for
oral anticoagulation (atrial fibrillation); concomitant participation in another clinical
trial. Lesions in the inflow arteries needing to be treated were submitted to standardised
treatment of femoropopliteal arteries
Interventions For all patients eligible for the trial, antegrade access was chosen. After a 6 F sheath (Brite
Tip,Cordis, Johnson&Johnson,NewBrunswick,NJ,USA)was introduced, a diagnostic
angiogram was obtained. 3000 units of unfractionated heparin was administered
The target lesion in the infrapopliteal arteries was selected, and in case of successful
passage of the target lesion with a hydrophilic-coated guidewire (Standard Glide Wire,
0.035 inch, Terumo Medical Corporation, Somerset, NJ, USA; V-18, Control™Wire,
Boston Scientific, Marlborough, MA, USA; or Hi-Torque Sparta Core 14 Guide Wire,
Abbott Vascular, Abbott Park, IL, USA) and the help of a support catheter, the randomi-
sation process was done as described above
If the lesion could not be passed with a guidewire, the patient was not included. To secure
standardised documentation of the target lesion, a measuring tape was applied, leading
down from the popliteal fossa to the foot of the patient. Before and after the procedure,
angiography was performed in 2 planes, with a difference in angle of at least 30 degrees.
In case of lesions in the inflow arteries, these were treated before the revascularisation
procedure of the infrapopliteal arteries was performed
PTA group:
• The procedure was performed with the Amphirion Deep catheter (Invatec S.r.l.,
Roncadelli (Bs), Italy)
Stenting group:
• Primary stent placement was performed with a balloon expandable stent with a
silicon-carbide coating - the Motion Explorer Stent (Biotronik, GmbH&Co. KG,
Berlin, Germany). Stents with a diameter of 2.5 mm up to 3.5 mm and a length of 15
mm up to 25 mm were used. The lesion was exactly calculated using a programme for
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measurements. A 0.014-inch guidewire (HI Torque, Sparta Cor 14, Guidant
Corporation, Santa Clara, CA, USA) was used for PTA and stenting procedures
Medication:
• The evening before the procedure, the participant received 300 mg clopidogrel;
after the procedure, all participants were treated with low-molecular-weight heparin
(enoxaparin 40 mg twice daily) for 48 hours
• Immediately after the procedure, the participant was put on a dual platelet
aggregation therapy, with aspirin 100 mg a day and clopidogrel 75 mg a day for 3
months
• 3 months post procedure, participants were put on aspirin 100 mg a day as long-
term prophylactic therapy
Outcomes The main study endpoint was 1-year clinical benefit, defined by improvement of at least
1 Rutherford category compared to baseline
Quote: “Follow-up examinations for all patients in the trial were performed the day
aft er the successful procedure, at month 3, 6 and 12 thereafter. At each date a clinical
evaluation referring to the Rutherford classification was done. In case of Rutherford
classification 5 - 6 the wound was measured geometrically and compared in size to the
prior visits. For rest pain evaluation, a standardised pain scale (NRS, numeric rating
scale) was used. Walking distance was evaluated by treadmill testing. Ankle brachial
index (ABI) and colour coded duplex sonography of the target lesion were done at each
visit. The target lesion was targeted by duplex sonography referring to the measurement
during the intervention. A measuring tape was once again applied leading down from
the popliteal fossa to the foot of the patient to refind the formerly treated lesion. Colour
coded duplex sonography was performed by two experienced study technicians and
included an evaluation of the whole artery treated. The definition of 70% re-stenosis
was based on a proximal PVR > 3,4 calculated on duplex ultrasound. PVR was defined
as peak systolic flow velocity in the lesion divided by the peak systolic flow velocity ~1
cm proximal to the lesion. If a relevant re-obstruction was suspected digital subtraction
angiography (DSA) was performed, and at month 12 all patients underwent magnetic
angiography (MRA). In all patients at each time of evaluation concomitant medication
and medical events (especially cardiovascular events) were taken”
Secondary endpoints were 3-month and 6-month primary patency rate; 3-, 6-, and 12-
month secondary patency; and 12-month target lesion revascularisation rate
The second primary endpoint was 12-month primary patency, defined as freedom from
re-stenosis > 70% detected with duplex ultrasound
Quote: “The definition of 70% restenosis was based on a proximal PVR > 3,4 calculated
on duplex ultrasound. PVRwas defined as peak systolic flow velocity in the lesion divided
by the peak systolic flow velocity ~1 cm proximal the lesion”
Major adverse events were any amputation, the need for acute surgical revascularisation,
and death related to the procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “The randomisation process was
conducted with a computer-generated list
(blocked randomisation)”
Allocation concealment (selection bias) Low risk Quote: “The patients were listed for pri-
mary stent implantation or PTA alone with
the usage of sequential numerated closed
envelopes, which contained information
about the planned procedure”
Quote: “The blinding was warranted due
to sealed envelopes and randomisation was
done in the catheter lab immediately after
successful passing of the target lesion with
the guide wire. The randomisationwas per-
formed per patient”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk None
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “The whole follow up period of 12
months was completed by 44 patients. 9
patients (16.7%) had died, 8 due to car-
diovascular death, one had developed lung
cancer. One patient refused to show up for
the follow up visits after 3 months”
No ITT analysis was performed
Selective reporting (reporting bias) Low risk None
Other bias High risk Quote: “Originally the trial was planned
as a multicenter trial with the appropriate
randomisation therefore, but at the end it
was performed as a monocentric study, be-
cause the other participating centers had
difficulties including appropriate patients.
They did not include any patient over the
whole study period. This explains the dif-
ferent numbers of patients in the two treat-
ment groups”
Quote: “At baseline evaluation all cardio-
vascular risk factors were more pronounced
in the stent group than in the PTA group,
with the biggest and statistically significant
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difference in hyperlipidemia in spite of lipi-
demic treatment (n = 14 (66.7%) versus 6
(18.2%); P < 0.0001). For diabetes melli-
tus, concerning the fact of insulin therapy
there was a difference between the stent and
PTA group, too (47.6% versus 36.4%)”
Rand 2006
Methods Country: Austria
Setting: hospital
Study design: RCT
Level of randomisation: participant
Participants No. of participants randomised: The study population consisted of 51 patients who
were treated for critical chronic limb ischaemia (Fontaine stages III and IV), defined
as rest pain, ischaemic ulcer, and gangrene. Patients with only claudication were not
included in this study
Exclusions post randomisation: none
Number of participants evaluated: 51 participants with 95 lesions: PTA group: 27
participants (53 lesions), stent group: 24 participants (42 lesions)
Shifted to another arm: none
Number of participants evaluated: 51; 44 were consecutively investigated and ran-
domised at 1 centre to treatment of lesions by either PTA or stent application; 7 from 2
other centres were enrolled
Age (mean), years: 72; mean age for the individual group not specified
Gender: did not specify
Inclusion criteria: chronic critical limb ischaemia stages III and IV of the Fontaine
classification; isolated stenosis > 70% or occlusion of the tibial arteries; up to 3 lesions;
lesions that were up to 3 cm with cumulative lesion length ≤ 9 cm, including the
tibiofibular trunk, anterior and posterior tibial arteries, and fibular artery. There was no
further limitation regarding lesion position. Patients with a significant inflow obstruction
at the pelvic or superficial femoral artery level were not included
Exclusion criteria: evidence of a systemic coagulopathy with anticoagulant and an-
tiplatelet treatment contraindicated; previously implanted stents in the target lesion; to-
tal occlusion in the target vessel following the target lesion; without distal runoff; in-
flammatory vascular disease; peptic ulcer or gastric/intestinal bleeding in the previous 6
months; clinically assessed intolerance to contrast medium
Interventions PTA group:
• Lesions were routinely treated with a 5 Fr conventional balloon angioplasty
catheter and guidewire (Bijou 2.5-4 mm, Boston Scientific, Galway, Ireland; guidewire
M 0.035-inch, Terumo, Tokyo, Japan)
Stenting group:
• Stent applications were performed with a 0.014-inch guidewire (HI Torque,
Sparta Core 14, Guidant Corporation, Santa Clara, CA) and carbostents (Sorin,
Biomedica, Italy) with diameter range of 2.0 to 4 mm and length of 15 to 25 mm
Medication:
• At the beginning of the procedure, 5000 units of heparin was administered intra-
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arterially
• Post-interventional anticoagulation therapy for the PTA group consisted of low-
molecular-weight heparin (Enoxaparin 2 to 40 mg) for 3 days and acetylsalicylic acid
(ASA; ThromboAss, 100 mg per day permanently)
• Adjunct therapy for the stent group consisted of clopidogrel (Plavix),
administered as a bolus of 300 mg on the day of the procedure and 75 mg per day
orally for 4 weeks, and ASA medication permanently
• Quote: “Due to its main effect on early restenosis clopidogrel is given only to
patients who have received stents and not to patients who underwent PTA, as early
restenosis is not regarded a major problem in this patient group”
Outcomes Primary endpoint:
• 6-month angiographic patency rate of treated lesions, which was defined as re-
stenosis < 70% (threshold 1: critical re-stenosis) or < 50% (threshold 2: subcritical re-
stenosis), documented by CTA or DSA
Secondary endpoints:
• Minor and major amputations; major amputation referred to amputation above
the metatarsal line
• Complications were classified according to recommended standards: major
complications cause death, cause permanent disability, or necessitate revascularisation
or other invasive treatment, or a prolonged hospital stay. Less significant complications
were classified as minor complications
• Surgical revascularisation
• Death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Random number generation not described
Allocation concealment (selection bias) Low risk Quote: “Numbered envelopes were pre-
pared for one-to-one randomization to ei-
ther PTA or primary stent placement. The
randomization was performed per patient.
Therefore, all lesions in a particular patient
had to be treated by either PTA or primary
stent placement”
Type of envelope not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not reported
Blinding of outcome assessment (detection
bias)
Low risk Data evaluation performed by the 2 readers
in a double-blinded fashion
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 51 patients, 2 patients died,
3 patients underwent amputation, 1 pa-
tient underwentmajor heart surgery, which
did not allow further follow-up, and 8 pa-
tients were lost to follow-up”
Survival analysis performed
Selective reporting (reporting bias) Low risk None
Other bias Unclear risk Quote: “Due to its main effect on early
restenosis clopidogrel is given only to pa-
tients who have received stents and not
to patients who underwent PTA, as early
restenosis is not regarded a major problem
in this patient group”
Quote: “We also observed a higher inci-
dence of PTAs than stent applications per
patient. This might be due to a certain de-
gree of investigator bias, as potentially one
balloon can be used for several lesions in
contrast to the necessity of one stent per
lesion”
Quote: “The study was supported by the
LudwigBoltzmann Institute forRadiologic
Tumor Diagnosis and the Ludwig Boltz-
mann Institute of Interdisciplinary Vascu-
lar Research”
Rand 2011
Methods Country: InPeria II study at 6 centres in Europe (Austria, Italy, and Germany)
Setting: tertiary and university hospitals
Study design: RCT
Level of randomisation: limb
Participants No. of participants: 88 consecutive patients: PTA group: 44 participants; stent group:
44 participants
Age (mean), years: PTA group 62.2, stent group 68.2
Gender: PTA group 28 male/17 female, stent group 30 male/11 female
Exclusions post randomisation: none
Shifted to another arm: during the intervention in the PTA group, if residual stenosis (>
30%) and flow-limiting dissection were present, the participant was treated with stent;
thus the participant crossed over into the stent group
Number of participants evaluated: 88; 44 in the PTA group (45 treated limbs) and 44
in the stent group (44 treated limbs). Total: 131 treated lesions (PTA group: 69 lesions;
stent group: 62 lesions)
Losses to follow-up: 3 in the PTA group and 5 in the stent group died within the first
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3 months after treatment. Two additional participants in the PTA group died between
3 and 6 months after treatment. Fifteen participants were not available for follow-up
investigations at 3 months and an additional 20 participants were not available for
investigations at 9 months owing to death or non-compliance
Inclusion criteria: symptomatic CLTI (stage 4 or 5 according to the Rutherford classifi-
cation) due to a de novo lesion of an infrapopliteal artery. Lesions with stenosis≥ 50% of
their diameter were considered for the trial. Patients with substantial inflow stenosis were
eligible for inclusion if the stenosis had been successfully treated without complications.
The target infrapopliteal artery was eligible provided that in-line circulation to the foot
distal to the lesion was present
Exclusion criteria: previous treatment; total occlusion in the target vessel; no distal
arterial runoff; underlying disease (e.g. renal failure, bleeding disorders)
Interventions PTA group (control):
• Procedures were carried out with a Pegaso balloon (Sorin) when balloon length
was suitable for lesion length (lesion length 30 mm) or with any other peripheral
balloon when lesions were longer than 30 mm. Balloon diameter was selected to equal
diameter of the artery
Stenting group:
• Primary stenting was performed by using the InPeria Carbostent (Sorin), which is
a balloon expandable stainless steel slotted tube device characterised by a permanent
coating of a thin film of turbostatic carbon (Carbofi lm; Sorin)
Medication:
• After arterial cannulation, 5000 units of intra-arterial heparin was administered in
both study groups
• In the PTA group, participants were given 40 mg of enoxaparin twice daily for 3
days, and were put on 100 mg of aspirin daily indefinitely
• In the stent group, a loading dose of 300 mg of clopidogrel was given on the day
of the procedure, followed by 75 mg of clopidogrel daily for 4 weeks and aspirin
medication given permanently
Outcomes Primary endpoints assessed at 3 months and 9 months:
• Assessment of clinical improvement after endovascular treatment based on
American Heart Association Clinical Improvement Score after percutaneous
interventions.
• Limb salvage rate (minor vs major amputation).
Secondary endpoints assessed at 9 months:
• MLD before and after the revascularisation procedure
• Percentage of residual diameter stenosis (DS): defined as 100 [(RVD 2 MLD)/
RVD], where RVD is the reference vessel diameter
• Two binary re-stenosis rates (50% DS and 70% DS)
• Incidence of target lesion revascularisation at 9-month follow-up
Notes Data analysis performed in this review used limbs as unit of measurement instead of
treated lesion(s)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) High risk Quote: “Randomization (stent vs PTA)was
performed in a 1:1 ratio, so that all pa-
tients enrolled in this study were random-
ized to undergo either stent placement or
PTA alone for each leg separately. This
means each leg in each patient was treated
individually (stent vs PTA), but all lesions
in the same leg would have been treated
with the same procedure allocated to that
leg”
Method of allocation concealment not
specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data accounted for; ITT analysis re-
ported
Selective reporting (reporting bias) Low risk All outcomes reported; flow chart provided
Other bias Low risk Quote: “This study was pursued with sup-
port from Sorin Biomedica Cardio (Salug-
gia, Italy), which provided the investiga-
tional devices. The authors had complete
control of the data and information sub-
mitted for publication, which was firmly in
the hands of the Medical University of Vi-
enna and the Karl Landsteiner Society, St
Poelten, Austria, and was unbiased by in-
dustry”
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Methods Country: Belgium
Setting: Ghent University Hospital
Study design: single-centre RCT
Level of randomisation: participant
Participants No. of participants randomised: total of 38 limbs in 35 participants with critical limb
ischaemia were randomised to angioplasty (n = 22) or primary stenting (n = 16)
Exclusions post randomisation: 1 participant in the PTA group did not receive inter-
vention (n = 1); reason: stenosis < 70%
Shifted to another arm: none
Number of participants evaluated: 22 in the PTA group and 16 in the stenting group
Age (mean), years: 72 years old in both groups
Gender: PTA group: 14 male/8 female; stenting group: 6 male/10 female
Inclusion criteria: All patients with CLTI (Rutherford 4 to 6, Fontaine III and IV)
hospitalised at the Department of Vascular Surgery, Ghent University Hospital, for
primary angioplasty of 1 or more crural vessels were randomised to primary stenting or
angioplasty alone. For most patients, this was a last attempt before major amputation
because of intractable pain or tissue loss. Some had no adequate venous conduit or no
surgical target vessel, and the level of comorbidity was generally too high for general
anaesthesia (ASA scores III and IV). All patients with stenosis of 70% or occlusions
of the crural arteries were considered suitable for endovascular therapy. The length of
the lesion was not an exclusion criterion, as even stenoses or occlusions > 10 cm were
accepted (an exclusion criterion in most angioplasty studies and registries)
Exclusion criteria: acute limb ischaemia; multi-segmental inflow lesions (longer than 3
cm) above the knee; sepsis; myocardial infarction during previous 14 days; blue toe syn-
drome (microembolisation); inability to ambulate. Patients who needed bypass surgery
for popliteal or superficial femoral occlusions and those who needed simultaneous an-
gioplasty of the crural and more then one proximal vessel were excluded
Nine patients needed concomitant proximal angioplasty for stenosis: 6 patients at the
level of the popliteal artery, 2 at the level of the superficial femoral artery, and 1 at the
level of the common iliac artery. There were 20 men and 18 women. The mean age of
all patients did not diverge statistically from the mean age of the subgroups (72 ± 9.8
years; range 50 to 88 years). In 15 limbs, 2 arteries were treated, and in 1 patient, all 3
crural arteries: only 1 of these vessels was included in the study
Interventions Stenting group:
• The target lesion was pre-dilated. Both coronary balloon expandable stents
(Jostent, Jomed Benelux Multi-link Vision Coronary Stent, Abbott, Abbott Park, IL,
USA) and self-expandable stents (Astron Pulsar Stent, Biotronik, Berlin, Germany;
Xpert Stent, Abbott) were used
PTA group (control):
• Bijou Dilatation Balloon (Boston Scientific, Natick, MA, USA), Fox SV Balloons
(Abbott), or cutting balloons (Boston Scientific) were used
Additional intervention:
• Additional devices were used in 4 participants: 1 participant in the PTA group
had a residual stenosis of 50%, which was treated during the same procedure with a
cutting balloon (Boston Scientific), and in 3 participants, an Excimer laser was used to
cross the lesion
• Quote: “In five patients we performed a subintimal instead of a transluminal
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recanalisation (two in the stent group and three in the PTA group). When it was
impossible to cross the lesion, even with the use of an Excimer laser (used in three
patients), the procedure was considered a technical failure and patients were treated
conservatively, by bypass surgery, or with a major amputation, according to the runoff
state of the vessels and patient condition”
Medication:
• Heparin was administrated at a dose of 5000 IU at the beginning of the
intervention
• All participants were discharged on antiplatelet drugs: low-molecular-weight
heparin at a therapeutic dose for 1 week, 75 mg clopidogrel per day for 2 months, and
low-dose aspirin (< 160 mg) indefinitely
Outcomes • Primary patency at 6 months and 12 months, defined as clinical primary patency:
this means freedom from re-stenosis; occlusion with recurrence of ischaemic rest pain
or recurrence of ulceration, leading to redo angioplasty; bypass surgery; or major
amputation
• Secondary patency at 6 months and 12 months, defined as freedom from redo
angioplasty until recurrence of symptoms
• Limb salvage at 6 months and 12 months, defined as successful when a full-length
limb was preserved; an above-the-ankle amputation was considered a failure
• Patient survival at 6 months and 12 months
• Technical success, defined as the ability to cross the lesion and perform an
angioplasty with > 30% re-stenosis
Quote: “Patients were examined every 3 - 6 months after discharge till the end of the
trial. Standard duplex scanning was performed every 6 months by one independent
experienced investigator to exclude bias. The PSVwasmeasured over the stent if possible.
In the case of angioplasty alone the PSV was measured over the whole length of the
treated artery.When the PSVwas > 400 cm/s or when the treated artery was re-occluded,
and the patients showed recurrence of rest pain, cessation of ulcer healing, or a new ulcer,
a new angiography was performed. In most of the patients ABPI measurements were
not possible or not reliable due to calcifications of the vessels. We preferred duplex over
angiography for follow up because of the renal comorbidity of our patients and the fact
that the most important outcome for these patients is not patency of the vessel but relief
of rest pain and healing of their ulcers”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
by computer-generated randomization se-
quence”
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was con-
cealed by means of sealed, consecutively
numbered envelopes”
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Randon 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk None
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Standard duplex scanningwas per-
formed every 6months by one independent
experienced investigator to exclude bias”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk None
Other bias Unclear risk Declaration of conflict of interest not stated
in the paper
Spreen 2016
Methods Country: The Netherlands
Setting: 3 major vascular centres in the Netherlands
Study design: multi-centre RCT
Level of randomisation: participant
Participants No. of participants randomised: A total of 144 limbs in 137 patients with critical
limb ischaemia were randomised to angioplasty (69 limbs in 67 participants) or primary
stenting (75 limbs in 74 participants) (4 participants included for 2 limbs, with 1 limb
in each arm)
Exclusions post randomisation: 3 participants (3 limbs) in the PTA group did not
receive intervention; reasons: intermittent claudication, renal failure without dialysis,
and coagulation disorder. One participant (1 limb) in the stent group did not receive
intervention; reason: vessel too small. Overall, 64 participants (66 limbs) received the
allocated PTA intervention, and 73 participants (74 limbs) received the allocated stent
treatment
Shifted to another arm: none
Age (mean), years: PTA group 73, stent group 74
Gender: PTA group 47 male/17 female, stent group 49 male/24 female
Gender: PTA group: 14 male/8 female, stent group 6 male/10 female
Inclusion criteria: age > 18 years; if female patient with child-bearing potential, may
not be pregnant at study entry and must utilise reliable birth control for the duration of
participation in the study; must be willing and able to comply with the specified follow-
up evaluation; critical limb ischaemia, defined as Rutherford category 4 (ischaemic rest
pain), 5 (minor tissue loss), or 6 (major tissue loss); stenosis (> 50% luminal loss) or
occlusion of an infrapopliteal artery, including the tibiofibular trunk, the anterior tibial
artery, the posterior tibial artery, and the fibular artery; target lesion length ≤ 90 mm;
artery to be treated with diameter ≥ 2 mm and ≤ 6 mm; patent common iliac, external
iliac, superficial femoral, and popliteal artery on the ipsilateral side before randomisation,
possibly after treatment during the same session. At least 1 patent crural (anterior tibial,
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Spreen 2016 (Continued)
posterior tibial, or fibular) artery with expected unobstructed runoff to ankle level after
treatment
Exclusion criteria: acute limb ischaemia; previous amputation of affected limb at or
above ankle level; subacute limb ischaemia, which requires thrombolysis as first treatment
modality; active bleeding or bleeding diathesis; recent (≤ 3months) haemorrhagic stroke
or any other CNS abnormality with increased risk of haemorrhage, such as intracra-
nial neoplasm, arteriovenous malformation, intracranial aneurysm, or aneurysm repair;
gastrointestinal or genitourinary bleeding of clinical significance within the previous 6
weeks before treatment; aneurysm in common femoral, superficial femoral, or popliteal
artery on the ipsilateral side; surgical revascularisation involving the same limb within
30 days before the index procedure or planned surgical revascularisation of the same
limb within 30 days of the index procedure; previous implanted stent at the index site;
life expectancy < 6 months or other factors making clinical follow-up difficult; known
allergy to acetylsalicylic acid (aspirin), clopidogrel, heparin, or paclitaxel; known allergy
to contrast media; known heparin-induced thrombocytopaenia (HIT type 2); unable
or unwilling to tolerate anticoagulant, antiplatelet therapy, or contrast media; creati-
nine clearance 20 mL/min (as derived from Cockcroft-Gault formula); severely calcified
lesions with expected resistance to stenting; poor inflow due to ipsilateral stenosis or
occlusions of the iliac or femoropopliteal arteries that cannot be treated during the same
session; significant vessel tortuosity or other parameters prohibiting access to the lesions
and/or delivery of the stent; without (expected) distal runoff to the index site
Interventions Stenting group:
• In the treatment arm, target lesions were treated with balloon expandable
paclitaxel-eluting stainless steel stents (TAXUS Liberté; Boston Scientific, Natick, MA,
USA). If necessary, according to the operator, mainly in cases of occlusion, lesions were
pre-dilated. The full length of lesions was covered, and when necessary, overlapping
stents were deployed (maximum 3 stents allowed)
PTA group (control):
• A balloon with diameter matching the target vessel was advanced over the
guidewire and was inflated at the target lesion site. If bailout stenting was required
(secondary to post-PTA occlusion or flow-limiting dissection), only non-drug-eluting
bare-metal stents were allowed
Medication:
• During the procedure, 5000 international units of heparin was administered
intra-arterially
• Post procedure, all participants were prescribed 100 mg carbasalate calcium daily
indefinitely and 75 mg clopidogrel daily (with 300-mg loading dose) orally for ≥6
months
Outcomes Primary outcome:
• Patency per treated lesion at months, defined as ≤ 50% loss of luminal diameter
without re-intervention in the interim. If CTA was not available but digital subtraction
angiography or duplex sonography was available, patency of treated sites was scored by
those techniques
Secondary outcomes:
• Ischaemic categorisation of the treated leg by means of Rutherford classification
(at 6 months and 12 months), minor and major amputation (at or below vs above
ankle level, respectively) of the trial leg (at 6 months and 12 months), periprocedural
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(within 30 days) complications, serious adverse events, death
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence on
a 1:1 basis. Randomisation per limb and
stratified in blocks per centre. Block size (n
= 4) known only to the statistician
Allocation concealment (selection bias) Low risk Sealed and opaque envelope
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants, operators, and investigators
not blinded to treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data accounted for. ITT analysis re-
ported
Selective reporting (reporting bias) Low risk None
Other bias Unclear risk One study author has received speakers’
fees from Cordis Corporation, Fremont,
CA, USA; Cook Medical, Bloomington,
IN, USA; and AngioDynamics, Latham,
NY, USA
Tepe 2010
Methods Country: Germany
Setting: hospital
Study design: RCT
Level of randomisation: participant
Participants No. of participants randomised: 60 with current ulcers randomised
Exclusions post randomisation: not mentioned
Shifted to another arm: 3 participants received additional stent placement after primary
endpoint: 2 in the PTA group and 1 in the stenting group
Number of participants evaluated: 60 (63 limbs)
Age (mean), years: stenting group 72.8, PTA group 72.2
Gender: 42 males, 21 females
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Tepe 2010 (Continued)
Inclusion criteria: Rutherford stage 5 or 6 with current ulcers on the basis of arterial
disease; patent vessel to the distal lower leg; index lesion maximum 5 cm in length
Exclusion criteria: not mentioned
Interventions Sixty participants with current ulcers were randomly assigned to receive:
• Sirolimus-coated stent with abciximab (n = 14)
• Bare stent with abciximab (n = 16)
• PTA with abciximab (n = 14)
• PTA alone (n = 19)
Medication:
• During the intervention, participants received 5000 IU heparin intra-arterially
• All participants received a clopidogrel and acetylsalicylic acid bolus before the
intervention
• Abcximab (ReoPro) was administered as a bolus of 0.25 mg/kg BW (maximum
20 mg) and as a 12-hour intravenous infusion of 45 µg/kg BW diluted in 250 mL
saline and injected with 21 mL/h
• Post-procedure medication consisted of clopidogrel 75 mg daily for 8 weeks and
acetylsalicylic acid 100 mg daily as continuous medication
Concurrent stenoses of the inflow or outflow tract were treated in the same session by
PTA
Outcomes Angiographic endpoints consisted of primary re-stenosis at 2 months and 6 months and
overall patency. Re-stenosis was defined as re-narrowing of the index lesion by ≥ 50%
Clinical endpoints were healing of ulceration, amputation rate, and overall survival
Technical endpoints included technical success rate, subacute re-occlusions, and re-steno-
sis
Technical success was defined as < 30% residual stenosis after the intervention
Notes In the forest plot, the 4 groups were re-classified into 2 broad groups: stenting and PTA
Stenting group: sirolimus-coated stent with abciximab (n = 14) and bare stent with
abciximab (n = 16)
PTA group: PTA with abciximab (n = 14) and PTA alone (n = 19)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Random number generation not described
Allocation concealment (selection bias) High risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk None
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
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Incomplete outcome data (attrition bias)
All outcomes
High risk Total of 63 limbs in 60 participants ran-
domised
Quote: “In total, 44 patients were available
for follow up after two months and 37 pa-
tients after six months, respectively”
Selective reporting (reporting bias) Low risk None
Other bias High risk Study supported by Eli Lilly; no explicit
mention of the independence of the re-
search team
ABI: ankle-brachial index.
ABPI: ankle-brachial pressure index.
AMS: absorbable metal stent.
ASA: acetylsalicylic acid.
ASA: American Society of Anesthesiologists.
BW: body weight.
CFDU: colour flow Doppler ultrasound.
CLTI: chronic limb-threatening ischaemia.
CNS: central nervous system.
CTA: computed tomography angiography.
DS: diameter stenosis.
DSA: digital subtraction angiography.
HIT: heparin-induced thrombocytopaenia.
ITT: intention-to-treat.
LLL: late lumen loss.
MLD: minimal lumen diameter.
MRA: magnetic resonance angiography.
PSV: peak systolic velocity.
PTA: percutaneous transluminal angioplasty.
PVR: peak velocity ratio.
QVA: quantitative vascular angiography.
RCT: randomised controlled trial.
RVD: reference vessel diameter.
TLR: target lesion revascularisation.
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Bosiers 2012 Comparison of 2 different stents
Bradbury 2010 Description of severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic
Inter-Society Consensus II classification in the BASIL trial
Rastan 2011 Comparison of 2 different stents
Scheinert 2012 ACHILLES trial: RCT of stent vs angioplasty for treatment of infrapopliteal arterial disease. Rutherford stages 3 to
5 were included. As outlined in our protocol, we intended to include in our analysis only patients with Rutherford
stages 4 to 6. Further, the study did not provide subgroup data specific to stage 4 and 5 patients and thus is excluded
from the review
Schulte 2015 EXPAND trial: RCT of stent vs angioplasty for treatment of infrapopliteal arterial disease. Rutherford stages 3 to
5 were included. As outlined in our protocol, we intended to include in our analysis only patients with Rutherford
stages 4 to 6. Further, the study did not provide subgroup data specific to stage 4 and 5 patients and thus is excluded
from the review
Siablis 2007 Prospective, non-randomised, single-centre, controlled, double-arm study. Stenting was performed as a bailout
procedure for suboptimal angioplasty results (flow-limiting dissection, elastic recoil, or post-angioplasty residual
stenosis > 30%). In the first 29 participants, infrapopliteal stenting was performed with bare-metal stents (group
B), and in the other 29 participants, sirolimus-eluting stents were used (group S)
Siablis 2014 IDEA trial: RCT comparing paclitaxel-coated balloon angioplasty vs drug-eluting stents in long infrapopliteal
lesions. Inclusion criteria were Rutherford classes 3 to 6 and angiographically documented infrapopliteal disease
with minimum lesion length of 70 mm. As outlined in our protocol, we intended to include in our analysis only
patients with Rutherford stages 4 to 6. Further, the study did not provide subgroup data specific to stage 4 and 5
patients and thus is excluded from the review
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
NCT01644487
Trial name or title Self Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries (SENSBTK)
Methods Study type: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants Enrolment: 50
Age eligible for study: 20 to 80 years
Genders eligible for study: both
41Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01644487 (Continued)
Accepts healthy volunteers: no
Inclusion criteria:
• Symptomatic critical limb ischaemia (Rutherford 4 to 6)
• Signed informed consent
• Target lesion length < 8 cm by angiographic estimation
• Stenosis > 50% or occlusive atherosclerotic lesion of the ipsilateral infrapopliteal artery
• Reference vessel diameter should be 2.0 to 4.5 mm
Exclusion criteria:
• Known allergy to heparin, aspirin, or other anticoagulant/antiplatelet therapies or bleeding diatheses,
or unable, or unwilling, to tolerate such therapies
• Taking warfarin
• History of previous life-threatening contrast media reaction
• Currently enrolled in another investigational device or drug trial
• Currently breastfeeding, pregnant, or intending to become pregnant
• Mentally ill or retarded
• Acute critical limb ischaemia
• Major bleeding history within prior 2 months
• Severe hepatic dysfunction (> 3 times normal reference values)
• Significant leucopenia, neutropenia, thrombocytopenia, anaemia, or known bleeding diathesis
• Life expectancy < 1 year due to comorbidity
• Reference segment diameter not suitable for available stent design
• Previously implanted stent(s) or PTA at the same lesion site
• Inflow-limiting arterial lesions left untreated
Interventions Experimental group: a group of patients who will undergo subsequent primary stenting following successful
conventional balloon angioplasty
Active comparator: a group of patients who will undergo routine conventional balloon angioplasty alone
without stenting
Outcomes Primary outcome measures: angiographic binary re-stenosis rate (time frame: 12 months)
Starting date Study start date: July 2012
Estimated study completion date: July 2018
Estimated primary completion date: July 2017 (final data collection date for primary outcome measure)
Contact information Principal investigator contact: Seung Woon Rha, MD, PhD; 82226263020; swrha617@yahoo.co.kr
Contact: Yun Hyeong Cho, MD, PhD; 82318106776; princette@hanmail.net
Notes
PTA: percutaneous transluminal angioplasty.
42Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. PTA versus stent
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Technical success ITT 5 476 Odds Ratio (M-H, Fixed, 95% CI) 3.00 [1.14, 7.93]
2 Technical success TA 5 474 Odds Ratio (M-H, Fixed, 95% CI) 2.78 [1.04, 7.41]
3 Procedural complications ITT 5 360 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.01, 53.60]
4 Procedural complications TA 5 359 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.01, 47.70]
5 Primary patency < 6 months
ITT
3 456 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.37, 2.11]
6 Primary patency < 6 months TA 3 309 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.32, 3.00]
7 Amputation ITT 4 306 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.56, 3.22]
8 Amputation TA 4 252 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.59, 3.40]
9 Mortality ITT 6 497 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.43, 1.17]
10 Mortality TA 6 487 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.42, 1.15]
Analysis 1.1. Comparison 1 PTA versus stent, Outcome 1 Technical success ITT.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 1 Technical success ITT
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 72/74 64/75 31.7 % 6.19 [ 1.32, 28.97 ]
Rand 2006 41/42 52/53 20.2 % 0.79 [ 0.05, 12.99 ]
Rand 2011 62/62 66/69 9.2 % 6.58 [ 0.33, 129.95 ]
Randon 2010 14/16 20/22 38.9 % 0.70 [ 0.09, 5.58 ]
Tepe 2010 30/30 33/33 Not estimable
Total (95% CI) 224 252 100.0 % 3.00 [ 1.14, 7.93 ]
Total events: 219 (Stent), 235 (PTA)
Heterogeneity: Chi2 = 3.87, df = 3 (P = 0.28); I2 =23%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours PTA Favours Stent
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Analysis 1.2. Comparison 1 PTA versus stent, Outcome 2 Technical success TA.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 2 Technical success TA
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 70/72 64/75 32.0 % 6.02 [ 1.28, 28.18 ]
Rand 2006 41/42 52/53 20.1 % 0.79 [ 0.05, 12.99 ]
Rand 2011 62/62 67/69 9.3 % 4.63 [ 0.22, 98.32 ]
Randon 2010 14/16 20/22 38.6 % 0.70 [ 0.09, 5.58 ]
Tepe 2010 30/30 33/33 Not estimable
Total (95% CI) 222 252 100.0 % 2.78 [ 1.04, 7.41 ]
Total events: 217 (Stent), 236 (PTA)
Heterogeneity: Chi2 = 3.54, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours PTA Favours Stent
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Analysis 1.3. Comparison 1 PTA versus stent, Outcome 3 Procedural complications ITT.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 3 Procedural complications ITT
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosiers 2009 0/60 0/57 Not estimable
Brodmann 2011 0/21 6/33 45.2 % 0.10 [ 0.01, 1.84 ]
Rand 2011 0/44 0/44 Not estimable
Randon 2010 12/16 8/22 54.8 % 5.25 [ 1.26, 21.86 ]
Tepe 2010 0/30 0/33 Not estimable
Total (95% CI) 171 189 100.0 % 0.87 [ 0.01, 53.60 ]
Total events: 12 (Stent), 14 (PTA)
Heterogeneity: Tau2 = 7.54; Chi2 = 6.45, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Stent Favours PTA
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Analysis 1.4. Comparison 1 PTA versus stent, Outcome 4 Procedural complications TA.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 4 Procedural complications TA
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosiers 2009 0/60 0/57 Not estimable
Brodmann 2011 0/21 6/33 45.0 % 0.10 [ 0.01, 1.84 ]
Rand 2011 0/44 0/44 Not estimable
Randon 2010 12/16 8/21 55.0 % 4.88 [ 1.16, 20.45 ]
Tepe 2010 0/30 0/33 Not estimable
Total (95% CI) 171 188 100.0 % 0.84 [ 0.01, 47.70 ]
Total events: 12 (Stent), 14 (PTA)
Heterogeneity: Tau2 = 7.19; Chi2 = 6.19, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Stent Favours PTA
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Analysis 1.5. Comparison 1 PTA versus stent, Outcome 5 Primary patency < 6 months ITT.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 5 Primary patency < 6 months ITT
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosiers 2009 14/74 29/75 33.0 % 0.37 [ 0.18, 0.78 ]
Rand 2006 15/42 17/53 30.6 % 1.18 [ 0.50, 2.77 ]
Spreen 2016 47/121 27/91 36.4 % 1.51 [ 0.84, 2.69 ]
Total (95% CI) 237 219 100.0 % 0.88 [ 0.37, 2.11 ]
Total events: 76 (Stent), 73 (PTA)
Heterogeneity: Tau2 = 0.46; Chi2 = 8.82, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Stent Favours PTA
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Analysis 1.6. Comparison 1 PTA versus stent, Outcome 6 Primary patency < 6 months TA.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 6 Primary patency < 6 months TA
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosiers 2009 14/44 29/50 33.4 % 0.34 [ 0.14, 0.79 ]
Rand 2006 15/25 17/32 30.2 % 1.32 [ 0.46, 3.82 ]
Spreen 2016 42/81 27/77 36.4 % 1.99 [ 1.05, 3.78 ]
Total (95% CI) 150 159 100.0 % 0.97 [ 0.32, 3.00 ]
Total events: 71 (Stent), 73 (PTA)
Heterogeneity: Tau2 = 0.80; Chi2 = 10.90, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours Stent Favours PTA
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Analysis 1.7. Comparison 1 PTA versus stent, Outcome 7 Amputation ITT.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 7 Amputation ITT
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 2/60 2/57 22.8 % 0.95 [ 0.13, 6.97 ]
Rand 2011 5/44 2/44 20.4 % 2.69 [ 0.49, 14.69 ]
Randon 2010 3/16 2/22 15.8 % 2.31 [ 0.34, 15.75 ]
Tepe 2010 2/30 4/33 41.0 % 0.52 [ 0.09, 3.06 ]
Total (95% CI) 150 156 100.0 % 1.34 [ 0.56, 3.22 ]
Total events: 12 (Stent), 10 (PTA)
Heterogeneity: Chi2 = 2.17, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Stent Favours PTA
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Analysis 1.8. Comparison 1 PTA versus stent, Outcome 8 Amputation TA.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 8 Amputation TA
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 2/59 2/50 25.0 % 0.84 [ 0.11, 6.21 ]
Rand 2011 5/19 2/24 15.6 % 3.93 [ 0.67, 23.10 ]
Randon 2010 3/16 2/21 16.8 % 2.19 [ 0.32, 15.00 ]
Tepe 2010 2/30 4/33 42.6 % 0.52 [ 0.09, 3.06 ]
Total (95% CI) 124 128 100.0 % 1.41 [ 0.59, 3.40 ]
Total events: 12 (Stent), 10 (PTA)
Heterogeneity: Chi2 = 2.97, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Stent Favours PTA
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Analysis 1.9. Comparison 1 PTA versus stent, Outcome 9 Mortality ITT.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 9 Mortality ITT
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 1/60 1/57 2.7 % 0.95 [ 0.06, 15.54 ]
Brodmann 2011 3/21 6/33 10.9 % 0.75 [ 0.17, 3.39 ]
Rand 2011 5/44 5/44 12.0 % 1.00 [ 0.27, 3.73 ]
Randon 2010 4/16 7/22 12.0 % 0.71 [ 0.17, 3.03 ]
Spreen 2016 17/73 16/64 35.5 % 0.91 [ 0.42, 1.99 ]
Tepe 2010 4/30 12/33 26.9 % 0.27 [ 0.08, 0.96 ]
Total (95% CI) 244 253 100.0 % 0.71 [ 0.43, 1.17 ]
Total events: 34 (Stent), 47 (PTA)
Heterogeneity: Chi2 = 2.94, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Stent Favours PTA
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Analysis 1.10. Comparison 1 PTA versus stent, Outcome 10 Mortality TA.
Review: Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia
Comparison: 1 PTA versus stent
Outcome: 10 Mortality TA
Study or subgroup Stent PTA Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bosiers 2009 1/59 1/50 2.9 % 0.84 [ 0.05, 13.86 ]
Brodmann 2011 3/20 6/33 10.4 % 0.79 [ 0.17, 3.61 ]
Rand 2011 5/45 5/43 12.3 % 0.95 [ 0.25, 3.54 ]
Randon 2010 4/16 7/21 12.3 % 0.67 [ 0.16, 2.84 ]
Spreen 2016 17/73 16/64 35.4 % 0.91 [ 0.42, 1.99 ]
Tepe 2010 4/30 12/33 26.8 % 0.27 [ 0.08, 0.96 ]
Total (95% CI) 243 244 100.0 % 0.70 [ 0.42, 1.15 ]
Total events: 34 (Stent), 47 (PTA)
Heterogeneity: Chi2 = 2.86, df = 5 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours Stent Favours PTA
A D D I T I O N A L T A B L E S
Table 1. Classification of peripheral arterial disease: Fontaine stages and Rutherford categories
Fontaine Rutherford (adapted from table from Norgren 2007)
Stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild claudication I 1 Mild claudication
IIb Moderate to severe
claudication
I 2 Moderate claudication
I 3 Severe claudication
III Ischaemic rest pain II 4 Ischaemic pain at rest
IV Ulceration or gangrene III 5 Minor tissue loss
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Table 1. Classification of peripheral arterial disease: Fontaine stages and Rutherford categories (Continued)
III 6 Major tissue loss
Table 2. A proposed classification of stents by individual parameters
A proposed classification of stents by individual parameters (table from Nelken 2004)
Deployment method Balloon expandable/angioplasty or self-expanding
Geometry Closed cell, open cell, modified connectors; weave-braided, knit-
ted; spiral coil, helix
Construction materials Stainless steel, 316L, full hard stainless; tantalum; platinum; niti-
nol; cobalt alloys; bio-absorbable
Treated stents Coated stents and drug-eluting stents: metals, bound drugs (pas-
sivation), ceramics, polymers,
drug-eluting stents
A P P E N D I C E S
Appendix 1. CENTRAL search strategy, 22 March 2017
Search run on Wed Mar 22 2017
#1 MESH DESCRIPTOR Arteriosclerosis 869
#2 MESH DESCRIPTOR Arteriolosclerosis EX-
PLODE ALL TREES
0
#3 MESH DESCRIPTOR Arteriosclerosis Oblit-
erans
72
#4 MESH DESCRIPTOR Atherosclerosis 645
#5 MESHDESCRIPTORArterial OcclusiveDis-
eases
737
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(Continued)
#6 MESHDESCRIPTORIntermittentClaudica-
tion
726
#7 MESH DESCRIPTOR Ischemia 803
#8 MESH DESCRIPTOR Peripheral Vascular
Diseases EXPLODE ALL TREES
2236
#9 (atherosclero* or arteriosclero* or PVD or
PAOD or PAD ):TI,AB,KY
9508
#10 ((arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-oc-
clus* or steno* or restenos* or obstruct* or lesio*
or block* or harden* or stiffen* or obliter*) ):
TI,AB,KY
8384
#11 (peripheral near3 dis*):TI,AB,KY 3533
#12 (claudic* or IC):TI,AB,KY 3229
#13 (isch* or CLI):TI,AB,KY 24787
#14 arteriopathic:TI,AB,KY 7
#15 dysvascular*:TI,AB,KY 11
#16 (leg near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
99
#17 (limb near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
158
#18 ((lower near3 extrem*) near3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or ob-
struct* or lesio* or block* or harden* or stiffen*
or obliter*) ):TI,AB,KY
82
#19 MESH DESCRIPTOR Leg EXPLODE ALL
TREES WITH QUALIFIERS BS
1113
#20 MESH DESCRIPTOR Popliteal Artery 282
#21 MESH DESCRIPTOR Tibial Arteries 33
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(Continued)
#22 (((poplite* or fempop* or infrapopliteal or tibial
or tibiofibular or peroneal) near3 (occlus* or
reocclus* or re-occlus* or steno* or restenos*
or obstruct* or lesio* or block* or harden* or
stiffen* or obliter*) )):TI,AB,KY
244
#23 (below knee):TI,AB,KY 253
#24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
#13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21 OR #22 OR #23
45012
#25 MESH DESCRIPTOR Angioplasty
EXPLODE ALL TREES
4177
#26 (angioplas* or percutan* or PTA or venoplasty)
:TI,AB,KY
14283
#27 (recanali* or revascular*):TI,AB,KY 7840
#28 dilat*:TI,AB,KY 7797
#29 (balloon or baloon):TI,AB,KY 7197
#30 MESH DESCRIPTOR Endovascular Proce-
dures EXPLODE ALL TREES
6721
#31 endovascular:TI,AB,KY 1653
#32 MESHDESCRIPTORBloodVessel Prosthesis
EXPLODE ALL TREES
412
#33 MESHDESCRIPTORBloodVessel Prosthesis
Implantation EXPLODE ALL TREES
408
#34 MESH DESCRIPTOR Stents EXPLODE
ALL TREES
3323
#35 (stent* or graft* or endograft* or endoprosthe*)
:TI,AB,KY
25857
#36 powerlink or talent or excluder or aorfix or
zenith or endologix or anaconda or Triascular
or Cordis or Endurant or Quantum or Aneurx
or Ancure or Advanta or Intracoil or Zilver or
Luminex
591
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(Continued)
#37 #25 OR #26 OR #27 OR #28 OR #29 OR #
30 OR #31 OR #32 OR #33 OR #34 OR #35
OR #36
48585
#38 #24 AND #37 10184
#39 coronary:TI 17747
#40 renal:TI 12744
#41 myocardial:TI 11080
#42 heart:TI 16995
#43 (carotid OR cerebral OR stroke):TI 26794
#44 #39 OR #40 OR #41 OR #42 OR #43 79250
#45 #38 NOT #44 4490
Appendix 2. Database searches, 25 June 2018
Source Search strategy Hits retrieved
CENTRAL via CRSO #1 MESH DESCRIPTOR Arteriosclerosis 946
#2 MESH DESCRIPTOR Arteriolosclerosis EX-
PLODE ALL TREES 0
#3 MESH DESCRIPTOR Arteriosclerosis Obliter-
ans 78
#4 MESH DESCRIPTOR Atherosclerosis 1057
#5 MESH DESCRIPTOR Arterial Occlusive Dis-
eases 818
#6 MESH DESCRIPTOR Intermittent Claudica-
tion 823
#7 MESH DESCRIPTOR Ischemia 1529
#8 MESH DESCRIPTOR Peripheral Vascular Dis-
eases EXPLODE ALL TREES 2772
#9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD ):TI,AB,KY 12059
#10 ((arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block* or
harden* or stiffen* or obliter*) ):TI,AB,KY 10524
#11 (peripheral near3 dis*):TI,AB,KY 4805
#12 (claudic* or IC):TI,AB,KY 4059
1911
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(Continued)
#13 (isch* or CLI):TI,AB,KY 31792
#14 arteriopathic:TI,AB,KY 7
#15 dysvascular*:TI,AB,KY 20
#16 (leg near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)):TI,AB,KY 130
#17 (limb near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*) ):TI,AB,KY 218
#18 ((lower near3 extrem*) near3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or obstruct*
or lesio* or block* or harden* or stiffen* or obliter*)
):TI,AB,KY 106
#19 MESH DESCRIPTOR Leg EXPLODE ALL
TREES 2795
#20 MESH DESCRIPTOR Popliteal Artery 301
#21 MESH DESCRIPTOR Tibial Arteries 37
#22 ((poplite* or fempop* or infrapopliteal or tibial
or tibiofibular or peroneal) near3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or obstruct*
or lesio* or block* or harden* or stiffen* or obliter*)
):TI,AB,KY 340
#23 (below knee):TI,AB,KY 299
#24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16 OR #17 OR #18 OR #
19 OR #20 OR #21 OR #22 OR #23 58387
#25 MESH DESCRIPTOR Angioplasty EX-
PLODE ALL TREES 4285
#26 (angioplas* or percutan* or PTA or venoplasty)
:TI,AB,KY 17853
#27 (recanali* or revascular*):TI,AB,KY 9723
#28 dilat*:TI,AB,KY 9421
#29 (balloon or baloon):TI,AB,KY 8392
#30 MESH DESCRIPTOR Endovascular Proce-
dures EXPLODE ALL TREES 7420
#31 endovascular:TI,AB,KY 2483
#32 MESH DESCRIPTOR Blood Vessel Prosthesis
EXPLODE ALL TREES 430
#33 MESH DESCRIPTOR Blood Vessel Prosthesis
Implantation EXPLODE ALL TREES 432
#34MESHDESCRIPTOR Stents EXPLODE ALL
TREES 3725
#35 (stent* or graft* or endograft* or endoprosthe*)
:TI,AB,KY 32859
#36 (powerlink or talent or excluder or aorfix or
zenith or endologix or anaconda or Triascular or
Cordis or Endurant or Quantum or Aneurx or An-
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cure or Advanta or Intracoil or Zilver or Luminex ):
TI,AB,KY 791
#37 #25 OR #26 OR #27 OR #28 OR #29 OR #
30 OR #31 OR #32 OR #33 OR #34 OR #35 OR
#36 61169
#38 #24 AND #37 13389
#39 coronary:TI 20963
#40 renal:TI 15210
#41 myocardial:TI 12539
#42 heart:TI 20907
#43 (carotid OR cerebral OR stroke):TI 32775
#44 #39 OR #40 OR #41 OR #42 OR #43 95337
#45 #38 NOT #44 6176
#46 01/01/2017 TO 25/06/2018:CD 292648
#47 #45 AND #46 1911
Clinicaltrials.gov peripheral artery disease OR pvd | Angioplasty OR
stent OR stenting OR Endovascular Procedures |
Start date on or after 01/01/2017 | Last update
posted on or before 06/26/2018
42
ICTRP Search Portal peripheral artery disease OR pvd | Angioplasty OR
stent OR stenting OR Endovascular Procedures
16
MEDLINE 1 ARTERIOSCLEROSIS/ 56443
2 exp ARTERIOLOSCLEROSIS/ 149
3 Arteriosclerosis Obliterans/ 3974
4 ATHEROSCLEROSIS/ 30942
5 Arterial Occlusive Diseases/ 26481
6 Intermittent Claudication/ 7594
7 ISCHEMIA/ 47483
8 exp Peripheral Vascular Diseases/ 50011
9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 170972
10 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 142839
11 (peripheral adj3 dis*).ti,ab. 37713
12 (claudic* or IC).ti,ab. 61912
13 (isch* or CLI).ti,ab. 345304
14 arteriopathic.ti,ab. 162
15 dysvascular*.ti,ab. 216
16 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 707
17 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 1808
931
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(Continued)
18 (lower adj3 extrem* adj3 (occlus* or reocclus* or
re-occlus* or steno* or restenos* or obstruct* or lesio*
or block* or harden* or stiffen* or obliter*)).ti,ab.
1478
19 exp LEG/bs [Blood Supply] 25021
20 Popliteal Artery/ 8971
21 Tibial Arteries/ 1482
22 ((poplite* or fempop* or infrapopliteal or tibial
or tibiofibular or peroneal) adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 2222
23 below knee.ti,ab. 2705
24 or/1-23 771207
25 exp ANGIOPLASTY/ 59069
26 (angioplas* or percutan* or PTA or venoplasty).
ti,ab. 158270
27 (recanali* or revascular*).ti,ab. 63853
28 dilat*.ti,ab. 132027
29 (balloon or baloon).ti,ab. 58152
30 exp Endovascular Procedures/ 106227
31 endovascular.ti,ab. 41162
32 exp Blood Vessel Prosthesis/ 27389
33 exp Blood Vessel Prosthesis Implantation/ 20589
34 exp STENTS/ 68512
35 (stent* or graft* or endograft* or endoprosthe*).
ti,ab. 379475
36 (powerlink or talent or excluder or aorfix or zenith
or endologix or anaconda or Triascular or Cordis
or Endurant or Quantum or Aneurx or Ancure or
Advanta or Intracoil or Zilver or Luminex).ti,ab.
118081
37 or/25-36 858143
38 24 and 37 118933
39 coronary.ti. 187093
40 renal.ti. 255164
41 myocardial.ti. 143393
42 heart.ti. 279300
43 (carotid or cerebral or stroke).ti,ab. 565188
44 or/39-43 1350042
45 38 not 44 65413
46 randomized controlled trial.pt. 462606
47 controlled clinical trial.pt. 92454
48 randomized.ab. 414104
49 placebo.ab. 189646
50 drug therapy.fs. 2024675
51 randomly.ab. 292381
52 trial.ab. 430649
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(Continued)
53 groups.ab. 1805468
54 or/46-53 4223684
55 exp animals/ not humans.sh. 4466015
56 54 not 55 3651071
57 45 and 56 12116
58 (2017* or 2018*).ed. 1396008
59 57 and 58 931
Embase 1 arteriosclerosis/ 33965
2 exp arteriolosclerosis/ 598
3 peripheral occlusive artery disease/ 33214
4 atherosclerosis/ 136080
5 peripheral occlusive artery disease/ 33214
6 intermittent claudication/ 9762
7 ischemia/ 76632
8 exp peripheral vascular disease/ 1659635
9 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 236192
10 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 197030
11 (peripheral adj3 dis*).ti,ab. 54293
12 (claudic* or IC).ti,ab. 62619
13 (isch* or CLI).ti,ab. 501091
14 arteriopathic.ti,ab. 206
15 dysvascular*.ti,ab. 239
16 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 987
17 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 2663
18 (lower adj3 extrem* adj3 (occlus* or reocclus* or
re-occlus* or steno* or restenos* or obstruct* or lesio*
or block* or harden* or stiffen* or obliter*)).ti,ab.
2085
19 popliteal artery/ 8511
20 tibial artery/ 2626
21 ((poplite* or fempop* or infrapopliteal or tibial
or tibiofibular or peroneal) adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 3292
22 below knee.ti,ab. 3440
23 or/1-22 2005601
24 exp angioplasty/ 82655
25 angioplas*.ti,ab. 56519
26 (recanali* or revascular*).ti,ab. 98197
6301
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27 (balloon or baloon).ti,ab. 89610
28 exp endovascular surgery/ 30698
29 endovascular.ti,ab. 60580
30 exp blood vessel prosthesis/ 13367
31 exp stent/ 152155
32 (stent* or graft* or endograft* or endoprosthe*).
ti,ab. 525915
33 (powerlink or talent or excluder or aorfix or zenith
or endologix or anaconda or Triascular or Cordis or
Endurant or Quantum or Aneurx or Ancure or Ad-
vanta or Intracoil or Zilver or Luminex).ti,ab. 77069
34 or/24-33 819330
35 23 and 34 268004
36 coronary.ti. 248958
37 renal.ti. 321018
38 myocardial.ti. 187858
39 heart.ti. 353011
40 (carotid or cerebral or stroke).ti. 355251
41 or/36-40 1382539
42 35 not 41 155933
43 randomized controlled trial/ 506719
44 controlled clinical trial/ 460124
45 random$.ti,ab. 1312412
46 randomization/ 78443
47 intermethod comparison/ 236277
48 placebo.ti,ab. 273953
49 (compare or compared or comparison).ti. 470472
50 ((evaluated or evaluate or evaluating or assessed
or assess) and (compare or compared or comparing
or comparison)).ab. 1757754
51 (open adj label).ti,ab. 64655
52 ((double or single or doubly or singly) adj (blind
or blinded or blindly)).ti,ab. 209368
53 double blind procedure/ 151022
54 parallel group$1.ti,ab. 21843
55 (crossover or cross over).ti,ab. 93145
56 ((assign$ or match or matched or allocation) adj5
(alternate or group$1 or intervention$1 or patient$1
or subject$1 or participant$1)).ti,ab. 283623
57 (assigned or allocated).ti,ab. 332735
58 (controlled adj7 (study or design or trial)).ti,ab.
295615
59 (volunteer or volunteers).ti,ab. 224740
60 trial.ti. 251607
61 or/43-60 4046836
62 42 and 61 33396
63 (2017* or 2018*).em. 3617606
64 62 and 63 6301
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CINAHL S55 S53 AND S54 416
S54 EM 2017 OR EM 2018 367,971
S53 S40 AND S52 3,559
S52 S41 OR S42 OR S43 OR S44 OR S45 OR S46
OR S47 OR S48 OR S49 OR S50 OR S51 341,911
S51 MH “Random Assignment” 38,635
S50 MH “Single-Blind Studies” or MH “Double-
Blind Studies” or MH “Triple-Blind Studies” 32,720
S49 MH “Crossover Design” 11,198
S48 MH “Factorial Design” 919
S47 MH “Placebos” 8,351
S46 TX “multi-centre study” OR “multi-center
study” OR “multicentre study” OR “multicenter
study” OR “multi-site study” 4,480
S45 TX crossover OR “cross-over” 14,551
S44 AB placebo* 28,287
S43 TX random* 218,886
S42 TX trial* 250,284
S41 TX “latin square” 142
S40 33 NOT 39 15,078
S39 S34 OR S35OR S36 OR S37 OR S38 136,026
S38 TI carotid OR cerebral OR stroke 50,135
S37 TI heart 45,069
S36 TI myocardial 15,858
S35 TI coronary 27,524
S34 S23 AND S33 12,767
S33 S24 OR S25 OR S26 OR S27 OR S28 OR S29
OR S30 OR S31 OR S32 72,689
S32 TX powerlink or talent or excluder or aorfix
or zenith or endologix or anaconda or Triascular or
Cordis or Endurant or Quantum or Aneurx or An-
cure or Advanta or Intracoil or Zilver or Luminex 4,
750
S31 TX stent* or graft* or endograft* or endopros-
the* 34,651
S30 (MH “Stents+”) 10,010
S29 (MH “Blood Vessel Prosthesis”) 1,016
S28 TX balloon or baloon 6,736
S27 TX dilat* 10,252
S26 TX recanali* or revascular* 8,067
S25 TX angioplas* or percutan* or PTA or veno-
plasty 23,625
S24 (MH “Angioplasty+”) 8,925
S23 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
OR S20 OR S21 OR S22 90,560
416
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S22 TX below knee 1,665
S21TX (poplite* or fempop* or infrapopliteal or tib-
ial or tibiofibular or peroneal) n3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or obstruct*
or lesio* or block* or harden* or stiffen* or obliter*)
303
S20 (MH “Tibial Arteries”) 146
S19 (MH “Popliteal Artery”) 363
S18 (MH “Leg/SU”) 258
S17 TX (lower n3 extrem*) n3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)
122
S16 TX limb n3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*) 278
S15 TX (leg n3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*) 124
S14 TX dysvascular* 172
S13 TX arteriopathic 10
S12 TX isch* or CLI 39,424
S11 TX claudic* or IC 5,857
S10 TX peripheral n3 dis* 9,254
S9 TX (arter* or vascular or vein* or veno* or pe-
ripher*) n3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*) 12,664
S8 TX atherosclero* or arteriosclero* or PVD or
PAOD or PAD 26,395
S7 (MH “Peripheral Vascular Diseases+”) 10,402
S6 (MH “Ischemia”) 3,371
S5 (MH “Intermittent Claudication”) 852
S4 (MH “Arterial Occlusive Diseases”) 1,608
S3 (MH “Atherosclerosis”) 3,336
S2 (MH “Arteriosclerosis”) 4,829
S1 (MH “Arteriosclerosis”) 4,829
AMED 1 ARTERIOSCLEROSIS/ 78
2 ATHEROSCLEROSIS/ 221
3 Intermittent Claudication/ 73
4 ISCHEMIA/ 263
5 (atherosclero* or arteriosclero* or PVD or PAOD
or PAD).ti,ab. 802
6 ((arter* or vascular or vein* or veno* or peripher*)
adj3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*)).ti,ab. 458
7 (peripheral adj3 dis*).ti,ab. 435
0
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8 (claudic* or IC).ti,ab. 1024
9 (isch* or CLI).ti,ab. 1666
10 arteriopathic.ti,ab. 1
11 dysvascular*.ti,ab. 57
12 (leg adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 21
13 (limb adj3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block*
or harden* or stiffen* or obliter*)).ti,ab. 32
14 (lower adj3 extrem* adj3 (occlus* or reocclus* or
re-occlus* or steno* or restenos* or obstruct* or lesio*
or block* or harden* or stiffen* or obliter*)).ti,ab. 25
15 ((poplite* or fempop* or infrapopliteal or tibial
or tibiofibular or peroneal) adj3 (occlus* or reocclus*
or re-occlus* or steno* or restenos* or obstruct* or
lesio* or block* or harden* or stiffen* or obliter*)).
ti,ab. 87
16 below knee.ti,ab. 359
17 or/1-16 4609
18 (angioplas* or percutan* or PTA or venoplasty).
mp. [mp=abstract, heading words, title] 792
19 (recanali* or revascular*).ti,ab. 136
20 dilat*.ti,ab. 220
21 (balloon or baloon).ti,ab. 90
22 endovascular.ti,ab. 28
23 exp Stents/ 189
24 (stent* or graft* or endograft* or endoprosthe*).
ti,ab. 1604
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added a paragraph to the methods section to explain how we addressed unit of analysis issues regarding participant or limb
randomisation in this review.
We have added ’technical success’ as a primary outcome and have upgraded the outcome ’procedural complication’ to a primary
outcome.
Wehave removed target lesion revascularisation (TLR) andminor amputation as outcomemeasures. TLR, defined as repeat percutaneous
or surgical revascularisation of a lesion anywhere within the stent or within the 5-mm borders proximal or distal to the stent, is
dependent on the willingness of the operator to intervene, regardless of the patency of the treated target. We therefore decided that this
was not an appropriate outcome. Minor amputation of devascularised tissue/gangrene is considered part of the treatment for CLTI,
and although revascularisation is aimed at preventing further tissue loss, it does not affect the outcome of tissue that is not viable and
hence is considered not relevant as an outcome measure.
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